1
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------
FORM 10-K
------------------------
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED MARCH 30, 2001
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM __________ TO __________ .
COMMISSION FILE NUMBER: 000-20198
------------------------
CHOLESTECH CORPORATION
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
CALIFORNIA 94-3065493
(STATE OR OTHER JURISDICTION OF (I. R. S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NUMBER)
3347 INVESTMENT BOULEVARD
HAYWARD, CALIFORNIA 94545
(510) 732-7200
(ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE, OF
REGISTRANT'S PRINCIPAL EXECUTIVE OFFICES)
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT: NONE
SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:
COMMON STOCK, NO PAR VALUE
SERIES A PARTICIPATING PREFERRED STOCK, NO PAR VALUE
(TITLE OF CLASS)
------------------------
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of the registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [ ]
The aggregate market value of the voting stock held by non-affiliates of
the registrant, based on the closing sale price of the common stock on March 30,
2001 as reported on the NASDAQ National Market, was approximately $46,199,000.
Shares of common stock held by each officer and director and by each person who
owns 5% or more of the outstanding common stock have been excluded in that such
persons may be deemed to be affiliates. This determination of affiliate status
is not necessarily a conclusive determination for other purposes.
As of June 20, 2001, the registrant had outstanding 12,112,219 shares of
common stock.
DOCUMENTS INCORPORATED BY REFERENCE
The registrant has incorporated by reference into Part III of this Annual
Report on Form 10-K portions of its Proxy Statement for the 2001 Annual Meeting
of Shareholders to be held August 16, 2001.
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
2
CHOLESTECH CORPORATION
FORM 10-K
FOR THE YEAR ENDED MARCH 30, 2001
TABLE OF CONTENTS
PAGE
----
PART I
Item 1. Business.................................................... 1
Item 2. Properties.................................................. 18
Item 3. Legal Proceedings........................................... 18
Item 4. Submission of Matters to a Vote of Security Holders......... 19
PART II
Item 5. Market for Registrant's Common Equity and Related
Stockholder Matters......................................... 20
Item 6. Selected Consolidated Financial Data........................ 21
Item 7. Management's Discussion and Analysis of Financial Condition
and Results of Operations................................... 23
Item 7A. Quantitative and Qualitative Disclosures About Market
Risk........................................................ 42
Item 8. Financial Statements and Supplementary Data................. 43
Item 9. Changes in and Disagreements with Accountants on Accounting
and Financial Disclosure.................................... 43
PART III
Item 10. Directors and Executive Officers of the Registrant.......... 44
Item 11. Executive Compensation...................................... 44
Item 12. Security Ownership of Certain Beneficial Owners and
Management.................................................. 44
Item 13. Certain Relationships and Related Transactions.............. 44
PART IV
Item 14. Exhibits, Financial Statements Schedules and Reports on Form
8-K......................................................... 44
Signatures.................................................. 48
i
3
PART I
This Annual Report on Form 10-K, the exhibits hereto and the information
incorporated by reference herein contain "forward looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E
of the Securities Exchange Act of 1934, as amended, and such forward looking
statements involve risks and uncertainties. When used in this Report, the words
"expect," "anticipate," and "estimate" and similar expressions are intended to
identify forward looking statements. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from those
projected. These risks and uncertainties include those discussed below and those
discussed in "Management's Discussion and Analysis of Financial Condition and
Results of Operations" or incorporated by reference herein. Cholestech
Corporation ("we", "us" or "Cholestech") undertakes no obligation to publicly
release any revisions to these forward looking statements to reflect events or
circumstances after the date this Report is filed with the Securities and
Exchange Commission or to reflect the occurrence of unanticipated events.
ITEM 1. BUSINESS
GENERAL
In the past fiscal year, we engaged in three business activities:
- Diagnostic Products -- which develops, manufactures and markets our
Cholestech L-D-X(R) System (the "L-D-X System") which performs
near-patient diagnostic tests that assist in assessing the risk of heart
disease, certain liver diseases, and in the monitoring of therapy to
treat those diseases.
- WellCheck(TM) -- which conducts cholesterol testing within the United
States that assesses the risk of heart disease and assists in the
monitoring of therapy to treat that diseases.
- WellCheck.com -- which provides interactive tools to consumers through
the Internet to better assess the risk of heart disease and to monitor
and motivate personal health management of that disease.
Diagnostic Products currently manufactures and markets the L-D-X System,
including the L-D-X Analyzer and a variety of single-use test cassettes, in the
United States and internationally. The L-D-X System allows health care providers
to perform individual tests or combinations of tests with a single drop of blood
from a fingerstick within five minutes. Our current products measure and monitor
blood cholesterol, related lipids, glucose and liver function, and are used to
test patients at risk of or suffering from heart, diabetes or liver disease.
WellCheck currently provides cholesterol and related testing services and
education to the general public using the L-D-X System and creates opportunities
for sales of test cassettes manufactured by our Diagnostic Products business.
WellCheck's professionals provide high quality services and offer test event
expertise to both event sponsors and consumers. As part of our testing services,
we utilize our proprietary Test Event Activity Management System ("TEAMS")
technology which automates registration, data acquisition and information
management at promotional, corporate wellness and other consumer testing events
and provides consumers with a personalized risk assessment for heart disease.
Substantially all of WellCheck's revenue is derived from promotional programs
with major pharmaceutical companies marketing lipid-lowering statin drugs. We
believe an opportunity exists to further expand our testing services business in
the promotional, corporate wellness, retail markets and other convenient venues
which broaden consumer access to testing while assisting consumer product
companies, such as pharmaceutical companies, in customer acquisition. Our goal
is to develop the first nationwide consumer testing services company for chronic
diseases.
We launched WellCheck.com in October 1999 to develop website content and
our TEAMS technology to provide consumers with interactive tools to learn about
and manage heart disease. Based on our determination that adequate sponsor
funding for a retail-oriented, chronic disease management model roll out was
unavailable at present, we refocused on expanding our activities in the
promotional and corporate wellness markets. As a result, our WellCheck.com
business unit and its consumer-oriented website have been repositioned as a
technology support tool for our WellCheck testing business. In the fourth
quarter of fiscal
1
4
2001, we recorded a non-cash, non-recurring charge of $1.96 million to reflect
the impairment of certain intangible assets associated with the development of
WellCheck.com's website and database.
More recently we merged WellCheck.com into WellCheck. We intend to operate
and manage WellCheck and WellCheck.com as one business segment in fiscal 2002
and beyond.
MARKET OVERVIEW
We believe the market for our products and services exists where the
management of heart disease meets the growing consumer trend for personal health
management.
Heart disease consists of long lasting or frequently recurring illnesses
that, due to their protracted and serious nature, are costly to treat and
monitor. High cholesterol is a significant contributing factor to cardiovascular
diseases, which remain the number one cause of death in America and kill more
people than the next seven diseases combined. Heart disease is also the leading
cause of death among diabetics.
- The American Heart Association estimates that more than 61 million people
suffer from some form of cardiovascular disease, which is the leading
cause of death of adults in the United States and resulted in over
949,000 deaths in 1998.
- Based on the evidence of scientific studies, the National Cholesterol
Education Program ("NCEP") expert panel on the detection, evaluation and
treatment of high blood cholesterol in adults and the National Institutes
of Health ("NIH") in May 2001 issued new guidelines which are expected to
substantially increase the number of Americans being treated for high
cholesterol. Numerous research studies substantiate that reducing high
cholesterol levels, primarily LDL levels, significantly reduces the risk
of a coronary event. The number of Americans following therapeutic
lifestyle changes is expected to increase from 52 million to 65 million
and the number of prescribed cholesterol lowering drugs is projected to
increase from 13 million to approximately 36 million.
- According to the new NIH guidelines, it is estimated that approximately
101 million, or one out of every two adult Americans, should be treated
for the chronic condition of high cholesterol, which has been linked by
conclusive evidence to cardiovascular disease.
- Diabetes is estimated to afflict approximately 16 million people in the
United States, over a third of whom have not yet been identified as being
diabetic.
- Heart disease is the leading cause of diabetes-related deaths. Adults
with diabetes have heart disease death rates approximately two to four
times higher than adults without diabetes.
The current healthcare system in the United States, while historically
successful in treating acute conditions, was not designed to adequately serve
the growing need for preventive healthcare and the management of chronic
conditions such as heart disease. In addition, over 42 million Americans do not
have health insurance. Both of these factors are driving a growing trend towards
personal health management, which we believe we are uniquely positioned to
service by providing practical, economical and efficient tools and information
to address a widespread, growing need for convenient, accurate cholesterol
testing as a part of a disease management program which may reduce costs and
improve treatment. Our cost effective technologies:
- identify at risk patients via convenient testing venues;
- screen for heart disease by identifying individuals with elevated
cholesterol levels;
- monitor the ongoing condition of people with heart disease whose
treatment programs may involve long-term, complex drug therapies; and
- enable consumers to take a more active role in their personal health
management.
2
5
MARKET OPPORTUNITY FOR SPONSORS AND PARTNERSHIPS
Many consumer product companies are interested in reaching consumers who
may potentially be at risk for elevated cholesterol and therefore more likely to
purchase their products. Because our technology and services are designed to
meet the needs of consumers who wish to personally manage their cardiovascular
health, we are an attractive partner to these other companies.
Pharmaceutical companies have focused considerable resources on developing
drugs for the treatment of heart disease, diabetes and other chronic diseases.
While drug therapy is necessary for the overall treatment of chronic diseases,
diagnostic screening and the proper monitoring of therapy are also important in
both an effective program to manage chronic diseases and patient education.
Widespread diagnostic screening for chronic diseases helps in the early
identification of patients who may benefit from drug therapy. Effective
administration of drug therapies often requires careful therapeutic monitoring
of a drug's impact on body chemistry to ensure proper drug dosages, monitor
improvement and reduce the risk of side effects. Moreover, ongoing compliance
with drug therapy is necessary for effective treatment and reduces the risk to
patients of adverse side effects.
In addition, a wide range of non-pharmaceutical companies have developed
products which target consumers with cholesterol problems or interests. These
include the manufacturers of food, vitamins and other non-regulated
nutraceutical products which have features and benefits designed to reduce
cholesterol.
Some of the emerging issues in healthcare are the increase of self-insured
employers and the increase of health and quality-of-life programs offered by
employers to their employees. We are also well positioned to help these
companies provide programs which screen their employees for cardiovascular risk
and support cardiovascular health programs within the employer's provider plan.
We believe we are well positioned to meet the needs of potential sponsors
and partners. Our unique technology, easy and convenient service and interactive
tools create a personal interaction with the consumer, which may be expanded to
include other related products and services.
MARKET SEGMENTS
We specifically target our products and services at markets outside of
traditional hospital or clinical laboratories. These markets include:
- physician office laboratories, which are operated by physicians or groups
of physicians. The physician office laboratory market consists of
approximately 96,000 sites that are registered with the Health Care
Finance Administration, approximately 41,000 of which are registered to
perform only tests that have been waived under the Clinical Laboratory
Improvement Act ("CLIA waived");
- health promotion sites, which include a variety of locations such as
corporate wellness programs, fitness centers, health promotion service
providers, community health centers, public health programs, the United
States military and other independent screeners; and
- consumer events such as promotional sporting and social events and retail
venue events.
OUR STRATEGY
Our objective is to extend the technological capabilities and performance
of our core Diagnostic Products business to meet the anticipated need for
widespread community based testing for heart disease. We developed our WellCheck
testing business to integrate our traditional Diagnostic Products business with
a testing service to meet this projected need. By combining diagnostic products
with testing services we hope to achieve both financial and competitive
advantages due to increased market penetration, expanded sales of test cassettes
manufactured by our Diagnostic Products business and improved disease management
therapy and compliance.
3
6
The components of our strategy related to our Diagnostic Products business
include:
- Increase Market Penetration. We intend to further penetrate the physician
office laboratory and health promotion markets by increasing the number
of installed L-D-X Analyzers both domestically and internationally. We
have implemented marketing and related programs to increase awareness of
the advantages of the L-D-X System among health care providers, third
party payors and consumers. In addition, we have entered into strategic
relationships with major pharmaceutical companies to promote preventive
care testing with the L-D-X System as an important component of the
management of cholesterol-related disease.
- Expansion of Testing Technology. We intend to develop a more effective
and efficient platform technology and expand our range of multi-element,
single-use, disposable cassettes to address additional diagnostic tests
to screen for and manage chronic disease, such as our alanine
aminotransferase ("ALT") test, which was waived under CLIA by the United
States Food and Drug Administration in April 2001 and will assist in
monitoring the impact and potential adverse side effects on the liver
from lipid lowering and other therapies.
- Expansion of Cassette Usage. We intend to increase the sale of single-use
test cassettes through additional placement of L-D-X Analyzers,
development of new diagnostic tests and broadening the testing venues
offered by our WellCheck business.
- Expansion of Manufacturing Capabilities and Efficiencies. We intend to
expand our manufacturing capacity by completing a third line for the
manufacture of cassettes, which is currently in a pre-production
validation stage and should be in full operation in July 2001.
Additionally, we will seek to introduce new manufacturing technologies to
improve the key performance attributes of our manufacturing process,
including quality, yields and efficiencies.
- Expansion of Distribution Relationships. We intend to augment our sales
and marketing efforts by continuing to establish relationships with
select third party distributors to strategically access and service our
markets in the United States and internationally.
The components of our strategy related to our WellCheck business include:
- Broaden Consumer Testing. We intend to broaden the geographic coverage of
our WellCheck testing services by furthering our expansion in the
promotional and corporate wellness markets, expanding into the retail
market and other convenient venues designed to increase consumer access
and acquiring additional regional testing companies. In addition, an
expansion of our consumer testing services will create opportunities for
sales of test cassettes manufactured by our Diagnostic Products business.
- Improve Consumer Access to Testing. We intend to focus on testing outside
of clinical or hospital laboratories by providing products and services
that improve people's access to cholesterol-related disease risk
assessment and management. We believe that more convenient testing will
increase the frequency of diagnostic testing and may lead to earlier
identification of patients at risk of or suffering from
cholesterol-related diseases.
- Enhance TEAMS Technology. We have developed, and intend to enhance, our
software for test event activity management, which is a proprietary
interactive testing program designed to facilitate the operation of a
cholesterol-related disease testing event using the L-D-X System by
providing data acquisition and patient information management to both the
event sponsor and the consumer.
- Further Develop Strategic Relationships and Business Partnerships. We
have established and intend to further develop strategic relationships to
improve penetration of our target markets. In particular, we intend to
further our alliances with major pharmaceutical companies and other
companies interested in health promotion to position our products and
services as the preferred tools for the personal health management for
cholesterol-related diseases. We also intend to provide companies
interested in targeting consumers who are at risk for cholesterol-related
diseases a more effective, direct means of interacting with consumers.
For example, we currently have two contracts to provide screening for a
major pharmaceutical manufacturer through our relationship with GMR
Marketing, an Omnicom
4
7
DAS agency which is a leader in sports, mobile, music/entertainment,
ethnic, and lifestyle marketing and produces major events on a nationwide
basis on behalf of its clients.
We merged WellCheck.com into WellCheck. We intend to leverage the synergies
of the two segments into a more efficient business. The merger became effective
in June 22, 2001.
PRODUCTS AND PRODUCTS UNDER DEVELOPMENT
We offer a variety of products and services in each of our businesses,
including products currently under development.
DIAGNOSTIC PRODUCTS
Diagnostic Products manufactures, markets and develops diagnostic testing
technology which facilitates the performance of near patient diagnostic testing
to assist in assessing the risk of certain cholesterol-related diseases, certain
liver diseases, and in the monitoring of therapy to treat those diseases.
Diagnostic Products currently manufactures and markets the L-D-X System,
including the L-D-X Analyzer and a variety of single-use test cassettes, in the
United States and internationally.
Overview of the Cholestech L-D-X(R) System
The L-D-X System is an easy to use, multi-element testing system consisting
of a telephone-sized analyzer, a variety of single-use, credit card-sized test
cassettes, a printer and accessories. The L-D-X System allows health care
providers to perform individual tests or combinations of tests with a single
drop of blood within five minutes. No special training is required to operate
the L-D-X System, and the sample does not need to be pre-treated. To run a test,
the health care provider pricks the patient's finger, transfers a drop of blood
to the cassette's sample well, inserts the cassette into the L-D-X Analyzer's
cassette drawer and presses the "run" button. All further steps are performed by
the L-D-X System, which produces results comparable in accuracy to results from
larger, more expensive bench top and clinical laboratory instruments that are
not CLIA waived.
The design of the L-D-X System incorporates as much proprietary technology
as possible into the test cassettes and maintains the L-D-X Analyzer as a
platform that can be easily adapted as new tests and other product upgrades are
introduced. As health care providers perform different tests, the encoding on
the cassette's magnetic strip communicates test specific and calibration
information to the L-D-X Analyzer. Changes that cannot be captured on the
cassette's magnetic strip can be accomplished by changes to the L-D-X Analyzer's
removable read only memory software pack. This flexible design enables health
care providers to perform a variety of tests using the same L-D-X Analyzer and
to take advantage of new tests and other product upgrades without having to
purchase a new L-D-X Analyzer.
The L-D-X System includes software that performs cardiac risk assessments
using risk factor parameters developed from the Framingham study, a long term
study of cholesterol levels and cardiovascular disease.
The L-D-X Analyzer
The L-D-X Analyzer is a four-channel, reflectance photometer that measures
the amount of light reflected from the reaction surfaces of a test cassette and
incorporates a microprocessor with built-in software. The L-D-X Analyzer
contains a drawer for insertion of the cassette, three buttons for user
activation and a liquid crystal display to present the test results. Using the
information and instructions encoded on the cassette's magnetic strip, the L-D-X
Analyzer's built-in microprocessor regulates the reaction conditions, controls
the optical measurements of analyte concentrations on the cassette's reaction
pads, executes the required calculations and, within five minutes, displays the
results on the liquid crystal display. The results are displayed as a numerical
value of the level of the analyte tested and can be transferred to a printer,
computer or computer network.
The software calculates the numeric values of the test results and is
contained in a removable read only memory software pack mounted in an access
well on the bottom of the L-D-X Analyzer. We will continue to
5
8
upgrade the software as new products are developed, allowing health care
providers to easily replace the existing read only memory pack with a new pack
containing upgraded software. The L-D-X Analyzer, along with a printer,
accessories and starter pack, comprises a L-D-X System and currently has a
domestic list price of $1,995.
Cassette Products
Our line of single-use test cassettes for the L-D-X System incorporates
patented and licensed technology for distributing precisely measured plasma to
multiple reaction pads for simultaneous testing. Each cassette has three parts:
a main body that contains the sample well into which the blood sample is
dispensed, a reaction bar where plasma is transferred for analysis and a
magnetic strip encoded with test instructions and lot specific calibration
information for the various chemistries on the reaction pads. Capillary action
draws a drop of blood through a separation medium within the cassette, stopping
the cellular components of the blood while transferring a small volume of plasma
to the cassette's reaction pads. When the plasma contacts the reaction pads, the
dry chemistry reacts with the analytes in the plasma, producing color. The
intensity of color developed indicates the concentration of the analytes in the
plasma. The magnetic strip contains information needed by the L-D-X Analyzer to
convert the reflected color reading into a concentration level for the accurate
measurement of the analytes being tested. This automatic process means that the
health care provider does not have to interpret any color reaction, relate a
reading to a separate chart or input calibration information. Our available test
cassettes range in current domestic list price from $3.95 to $10.95 per cassette
and include up to four tests per cassette.
The following table summarizes our current products and products under
development:
PRODUCT REGULATORY STATUS(1)
------- --------------------
INSTRUMENT
L-D-X Analyzer FDA cleared; CLIA waived
CASSETTE PRODUCTS
Current
Total cholesterol FDA cleared; CLIA waived
Total cholesterol and High density FDA cleared; CLIA waived
lipoproteins
Lipid Profile FDA cleared; CLIA waived
(Total cholesterol/High density lipoproteins/
Calculated low density
lipoproteins/Triglycerides)
Total cholesterol and Glucose FDA cleared; CLIA waived
Total cholesterol/High density FDA cleared; CLIA waived
lipoproteins/Glucose
Lipid Profile plus Glucose FDA cleared; CLIA waived
Alanine Aminotransferase (AST) FDA cleared; CLIA waived
Under Development(2)
Aspartate Aminotransferase (ALT) Not filed or applied
In Feasibility Studies(3)
Glycated Hemoglobin Not filed or applied
Direct high density lipoproteins Not filed or applied
Direct low density lipoproteins Not filed or applied
High sensitivity C-Reactive Protein (CRP) Not filed or applied
---------------
(1) "FDA" means the United States Food and Drug Administration; "FDA cleared"
means the product has received clearance pursuant to Section 510(k) of the
Food, Drug and Cosmetics Act of 1938, as amended. "CLIA waived" means the
Food and Drug Administration has granted our application to classify the
product as having waived status with respect to the Clinical Laboratory
Improvement Act.
(2) Products under development are those that have completed the feasibility
phase of the commercialization process and have begun the development phase.
During the development phase, manufacturing processes are developed and
defined, initial lots are made using those manufacturing processes and
performance
6
9
against product specifications is demonstrated. The products under
development are then transferred to manufacturing prior to launch.
(3) Products in the feasibility phase of our commercialization process are
studied to determine the compatibility of the reagents with the single use
test cassette, and preliminary data is generated to indicate if the reagents
can perform to preliminary specifications.
Current Cassette Products
Our current cassette products are designed to measure and monitor blood
cholesterol, related lipids, glucose and alanine aminotransferase. Lipids travel
in the blood within water-soluble particles called lipoproteins.
- Total Cholesterol. This stand-alone test for measuring total cholesterol
("TC") was our first test, developed in conjunction with National
Cholesterol Education Panel guidelines issued in 1988.
- Total Cholesterol and High Density Lipoproteins Panel. The TC and high
density lipoproteins ("HDL") panel addresses current National Cholesterol
Education Panel guidelines regarding the nonfasting screening for the
risk of cardiovascular disease by testing both TC and HDL. HDL particles
circulate in the blood and can pick up cholesterol from arteries and
carry it to the liver for elimination from the body. HDL is sometimes
called "good cholesterol" because of this function.
We believe the TC and HDL panel is particularly useful in diagnostic
screening applications. This panel also calculates the ratio of TC to HDL, a
recognized measure of cholesterol induced cardiac risk.
- Lipid Profile. We offer a lipid profile cassette, which directly measures
TC, HDL and triglycerides. In addition, the lipid profile cassette
calculates estimated values for LDL and the ratio of TC to HDL. The
development of cardiovascular disease has been associated with three
lipoprotein abnormalities: high levels of LDL, high levels of very low
density lipoproteins ("VLDL") and low levels of HDL. LDL, the major
carrier of cholesterol, and VLDL, a major carrier of triglycerides in the
blood, have been shown to be associated with deposits of plaque on the
arterial wall. High levels of triglycerides can also lead to development
of such plaque. Accumulation of this plaque leads to a narrowing of the
arteries and increases the likelihood of cardiovascular disease. The
lipid profile cassette thus performs multiple tests in the diagnostic
screening and ongoing therapeutic monitoring of individuals who have high
LDL levels or who exhibit two or more other cardiovascular disease risk
factors. National Cholesterol Education Panel guidelines recommend that
health care providers perform three lipid profiles, each one week apart,
before initiating lipid lowering drug therapy.
- Total Cholesterol and Glucose Panel, Total Cholesterol/High Density
Lipoproteins/Glucose Panel and Lipid Profile plus Glucose
Panel. Recognizing the relationship between diabetes and abnormal lipid
levels, we developed a glucose test for the L-D-X System and combined it
with each of its three lipid related test panels. The resulting panels
provide input used in the diagnostic screening and therapeutic monitoring
of patients with diabetes, whether or not they are aware they are
diabetic, as well as of individuals who may be at risk for cardiovascular
disease.
- Alanine Aminotransferase. Patients undergoing certain drug therapies must
be monitored for increases in certain enzymes that are associated with
liver damage. The availability of an alanine aminotransferase ("ALT")
test combined with our lipid profile will allow health care providers to
monitor both the impact of and potential adverse side effects on the
liver from lipid lowering and diabetic therapies. We received 510(k)
clearance to market ALT in September 1999 and received CLIA waived status
in April 2001.
7
10
Cassette Products Under Development
Products listed under development are undergoing optimization of design,
performance testing, scale up, clinical trials, regulatory submissions and
transfer to production.
- Aspartate Amino Transferase. Patients undergoing certain drug therapies
must be monitored for increases in certain enzymes that are associated
with liver damage. The availability of an aspartate amino transferase
("AST") test in conjunction with the our ALT test would allow health care
providers to monitor both the impact of and potential adverse side effect
on the liver from lipid lowering and diabetic therapies. This cassette
product has completed the feasibility phase and is starting the
development process.
Cassette Products in Feasibility Studies
We are in various stages of feasibility studies for new cassettes that
would expand our product line for diagnostic testing. We may develop additional
tests depending on the progress of our existing development efforts and
available resources.
- Glycated Hemoglobin. Glycated hemoglobin (hemoglobin A1c) measurement is
an immunoassay test used by health care providers to assess a diabetic's
long-term compliance with prescribed diet and insulin usage. A relatively
high percentage of glycated hemoglobin to glucose indicates poor patient
compliance, which can lead to severe health problems. The American
Diabetes Association recommends at least semi-annual measurement of
glycated hemoglobin for all individuals with diabetes.
- Direct High Density Lipoproteins. The direct HDL cholesterol test is able
to measure HDL cholesterol directly in the patient sample without the
need to remove the non-HDL cholesterol lipoproteins from the sample
before analysis, which takes place in the current HDL cholesterol test on
the L-D-X cassette. The direct HDL cholesterol test represents the next
generation of measurement of HDL cholesterol and is planned to replace
the current HDL cholesterol test.
- Direct Low Density Lipoproteins. The direct low density lipoproteins
("LDL") cholesterol test permits the direct measurement of LDL
cholesterol in a patient sample. The calculated LDL cholesterol is
subject to a number of limitations including the need for a fasting
sample. The direct LDL cholesterol test should be reimbursable, whereas
the calculated test is not reimbursable.
- High Sensitivity C-Reactive Protein. The high sensitivity C-reactive
protein ("CRP") test measures, by immunoassay, the amount of CRP present
in a patient sample. CRP is an independent risk factor for heart disease
and is useful in predicting the risk of future cardiovascular events.
WELLCHECK(TM)
WellCheck provides easy and economic testing for heart disease in venues
across the United States that are convenient to consumers.
Overview of WellCheck Testing Services
WellCheck currently provides cholesterol and related testing services and
education to the general public using the L-D-X System and creates opportunities
for sales of test cassettes manufactured by our Diagnostic Products business.
WellCheck's professionals provide high quality services and offer test event
expertise to both event sponsors and consumers. As part of our testing services,
we utilize our proprietary TEAMS technology which automates registration, data
acquisition and information management at promotional, corporate wellness and
other consumer testing events and provides consumers with a personalized risk
assessment for heart disease. Substantially all of WellCheck's revenue is
derived from promotional programs with major pharmaceutical companies marketing
lipid-lowering statin drugs. We believe an opportunity exists to further expand
our testing services business in the promotional, corporate wellness, retail
markets and other convenient venues which broaden consumer access to testing
while assisting consumer
8
11
product companies, such as pharmaceutical companies, in customer acquisition.
Our goal is to develop the first nationwide consumer testing services company
for chronic diseases.
We intend to seek opportunities to expand our WellCheck business through
both internal development and the assessment of additional acquisition or
partnership candidates to add more specific regional coverage to WellCheck's
testing services.
In addition, we continue to augment the capabilities of our TEAMS software,
a proprietary interactive testing program designed to facilitate the operation
of a cholesterol-related disease testing event using the L-D-X System. TEAMS is
used to capture participants' registration, self health assessment and results
from the L-D-X System while supporting event logistic processes. Information is
processed following National Cholesterol Education Program guidelines.
Individual participant reports, created for one to one education and consulting
with a WellCheck health promotion associate to assess an individual's results
and potential risk of heart disease based on the long-established Framingham
Study, can be provided immediately at the test site.
STRATEGIC RELATIONSHIPS
We have established and continually seek to develop strategic
relationships, which we believe will enhance the commercialization of our
products. In particular, we intend to enter into additional strategic alliances
with major pharmaceutical and other companies to enhance our market positioning
and our product offerings. Our current strategic relationships are described
below.
GMR Marketing Inc.
We have entered into numerous promotional programs with GMR Marketing Inc.,
a division of Omnicom ("GMR") in relation to the cholesterol-lowering statin
drug "Lipitor." These have included:
- "Screen Test For Health". GMR sponsored two WellCheck mobile screening
units to screen consumers for elevated cholesterol and cardiovascular
disease at promotional sporting events across the United States in 2000.
Three additional units have been added to the program and will conduct
testing through calendar 2001.
- "Tune Up For Life". GMR sponsored a WellCheck mobile screening unit to
provide men's health assessments across the United States in 2000 and
2001.
Physician Sales and Service, Inc.
We entered into a distribution partnership with Physician Sales and
Service, Inc. in 1996 for the distribution of our diagnostic products to
physician offices. Physician Sales and Service has been our largest single
customer for the last three years, contributing $6.1 million of revenue in
fiscal 2001, $4.6 million in fiscal 2000 and $3.4 million in fiscal 1999.
Merck and the American Pharmaceutical Association
In January 1996, the American Pharmaceutical Association announced Project
ImPACT (Improve Persistence And Compliance to Therapy), a joint effort between
the American Pharmaceutical Association, Merck & Co., Inc. ("Merck") and our
company (the "Project"). The goal of the Project was to demonstrate the ability
of pharmacists to improve patient outcomes by expanding the pharmacist's role in
chronic disease management, including monitoring the therapeutic effectiveness
of medications and providing counseling to patients. We and the American
Pharmaceutical Association believe that using pharmacists to provide such
services may result in both direct and indirect cost savings to patients and
third party payors, as well as provide economic incentives for pharmacists. We
supplied L-D-X Systems to monitor patients in the Project.
Directed by the American Pharmaceutical Association Foundation and funded
with an unrestricted educational grant from Merck and us, the Project involved
397 patients, 26 pharmacy practice sites in 12 states and over 60 pharmacists.
It was designed to demonstrate how pharmacists who act as disease
9
12
managers for patients with high cholesterol or lipid disorders can improve
persistence and compliance with therapy, working in collaboration with the
patient's physician.
In March 2000, we announced the final results of the Project at the
American Pharmaceutical Association's 147th Annual Meeting in Washington D.C.
The Project's final results, based on 24 months of data, demonstrated that
monitoring lipid levels at regular intervals and healthcare provider
collaboration, increased rates for persistence to 93.6% and for compliance with
medication therapy to 90.1%. The Project also found that 62.5% of these patients
had reached and maintained the National Cholesterol Education Panel's
cholesterol goals. These results represent a twofold to fourfold improvement
when compared to historical findings. In addition, the March/April 2000 issue of
the Journal of the American Pharmaceutical Association announced that our L-D-X
System played an integral part in helping participating health care providers
successfully manage patients with cholesterol disorders achieve optimal results.
SALES AND MARKETING
Our sales and marketing strategy is to capitalize on anticipated widespread
community based testing to identify individuals who require treatment for high
cholesterol and provide easy to use tools and information for therapeutic
monitoring. In order to fulfill this strategy, we intend to expand our
professional sales force and distribution capabilities, develop additional
venues for convenient consumer testing and market interactive tools for personal
health management directly to consumers, interested sponsors and partners.
Diagnostic Products
The sales and marketing strategy for our Diagnostic Products business is to
increase penetration into the physician office laboratory and health promotion
markets and leverage our installed base of L-D-X Analyzers through increased use
of cassettes. We plan to dedicate a significant portion of the sales and
marketing efforts of our Diagnostic Products business to educate current and
potential owners of L-D-X Systems about the clinical and economic benefits of
diagnostic screening and therapeutic monitoring with the L-D-X System and about
new test cassettes as they become available for distribution. We also plan to
continue to cultivate strategic relationships with development partners,
pharmaceutical companies and distributors. We intend to leverage the technology,
customer bases, marketing power and distribution networks of these partners to
accelerate market penetration and cassette usage. Diagnostic Products' current
marketing activities are primarily focused on:
- Physician Office Laboratories. We have entered into nonexclusive
distribution agreements with two national medical products distributors,
Physician Sales and Service and General Medical (currently a division of
McKesson Corporation), which together have more than 1,300 sales
professionals who focus on the physician office laboratory market. In
addition, we have retained more than 30 regional distributors. We and our
distributors focus our sales and marketing efforts on physicians whose
practices include a high incidence of the cholesterol-related diseases
targeted by our test cassettes, including cardiologists, lipid
clinicians, internists and family practitioners.
- Health Promotion. We have ongoing relationships with 15 regional
distributors who provide equipment and supplies to customers that conduct
diagnostic screening for cholesterol and related lipid levels and
diabetes. Additionally, through agreements with regional distributors and
screening organizations, we provide the L-D-X System for the diagnostic
screening of employees of Exxon Corporation, General Motors Corporation,
Ford Motor Company and Sears, Roebuck and Co.
- International. Our international distribution strategy is to penetrate
targeted geographic markets by selling directly to both high volume users
and distributors in those markets. We have entered into non-exclusive
agreements with 39 foreign distributors to distribute the L-D-X System,
primarily in Europe, the Pacific Rim and Latin America.
10
13
WellCheck
The sales and marketing strategy for our WellCheck business is to broaden
the geographic coverage of WellCheck's testing services and further penetrate
the promotional, corporate wellness and other consumer testing venue markets.
WellCheck's current marketing activities are primarily focused on:
- pharmaceutical companies;
- conventions;
- corporate wellness partners;
- retail venue partners; and
- public health programs.
COMPETITION
The diagnostic product markets in which we operate are intensely
competitive. Our competition consists mainly of clinical and hospital
laboratories, as well as manufacturers of bench top analyzers. The substantial
majority of diagnostic tests used by physicians and other health care providers
are currently performed by clinical and hospital laboratories. We expect that
these laboratories will compete intensely to maintain dominance in the market.
To achieve broad market acceptance, we must demonstrate that the L-D-X System is
an attractive alternative to benchtop analyzers and clinical and hospital
laboratories. This will require physicians to change their established means of
having such tests performed. There can be no assurance that the L-D-X System
will be able to compete with these other analyzers and testing services.
Companies with a significant presence in the diagnostic products market,
such as Abbott Laboratories, Beckman Coulter, Inc. and Roche Diagnostics (a
subsidiary of Roche Holdings Ltd.), have developed or are developing analyzers
designed for preventive care testing. These competitors have substantially
greater financial, technical, research and other resources and larger, more
established marketing, sales, distribution and service organizations than us.
Such competitors also offer broader product lines than us, have greater name
recognition than us and offer discounts as a competitive tactic. In addition,
several smaller companies are currently making or developing products that
compete or will compete with ours. We believe we currently have a competitive
advantage due to the status of the L-D-X System as the only CLIA waived system
capable of performing multiple tests simultaneously on a single instrument. We
expect that our competitors will compete actively to maintain and increase
market share and will seek to develop multi-analyte tests that qualify for CLIA
waiver. There can be no assurance that our competitors will not succeed in
obtaining CLIA waived status for their products or in developing or marketing
technologies or products that are more effective and commercially attractive
than our current or future products, or that would render our technology or
products obsolete or noncompetitive.
Our WellCheck business is one of numerous preventive care testing services
across the United States. Competing testing services companies are almost
exclusively regional and privately held, with limited access to capital. While
we believe the market opportunity for nationwide consumer testing of cholesterol
vastly exceeds the current ability of all existing testing services combined,
there is no guarantee that a larger, more well-known company with greater access
to capital than us may not choose to take advantage of this market opportunity
by competing with us.
Our current and future products must compete effectively with the existing
and future products of our competitors primarily on the basis of ease of use,
breadth of tests available, market presence, cost effectiveness, accuracy,
immediacy of results and the ability to perform tests near the patient, to test
multiple analytes from a single sample and to conduct tests without a skilled
technician or pre-treating blood. There can be no assurance that we will have
the financial resources, technical expertise or marketing, distribution or
support capabilities to compete successfully in the future or, if we do have
such resources and capabilities, that we will employ them successfully.
11
14
MANUFACTURING
We manufacture, test, perform quality assurance on, package and ship our
products from our approximately 47,000 square foot facilities located in
Hayward, California. We maintain control of those portions of the manufacturing
process that we believe are complex and provide an important competitive
advantage.
- L-D-X Analyzer. The L-D-X Analyzer incorporates a variety of
subassemblies and components designed or specified by us, including an
optical element, microprocessors, circuit boards, a liquid crystal
display and other electrical components. These components and
subassemblies are manufactured by a variety of third parties and are
shipped to us for final assembly and quality assurance. Our manufacture
of the L-D-X Analyzer consists primarily of assembly, testing, inspection
and packaging. Testing consists of a burn-in period, functional tests and
integrated system testing using specially produced test cassettes. We
believe we can expand our current L-D-X Analyzer manufacturing capacity
as needed.
- Cassettes. We purchase chemicals, membranes and other raw materials from
third party suppliers and convert these raw materials, using proprietary
processes, into single-use test cassettes. We believe our proprietary
processes and custom designed equipment are important components of our
cassette manufacturing operations. We have developed core manufacturing
technologies, processes and production machinery, including membrane
lamination and welding, discrete membrane impregnation, on-line
calibration and software control of the manufacturing process. We have
two fully operational cassette manufacturing lines. We are currently
building a third manufacturing line, which is currently in preproduction
validation stage and should be fully operational in July 2001.
- Raw Materials and Quality Assurance. Outside vendors provide us with the
subassemblies, components and raw materials necessary for the manufacture
of our products. These subassemblies, components and raw materials are
inspected and tested by our quality control personnel. Our quality
control personnel also perform finished goods quality control and
inspection and maintain documentation for compliance with quality systems
regulations and other government manufacturing regulations. Our
manufacturing facilities are subject to periodic inspection by regulatory
authorities. Certain key components and raw materials used in the
manufacturing of our products are currently provided by single source
vendors and on a purchase order basis.
PATENTS AND PROPRIETARY TECHNOLOGY
We have nine United States patents covering various technologies, including
the method for separating HDL from other lipoproteins in a dry chemistry format,
the basic design of the testing cassette and the L-D-X Analyzer and the method
of correcting for the effects of substances that can interfere with testing of a
blood sample. We have also filed patent applications relating to our technology
internationally under the Patent Cooperation Treaty and individual foreign
applications. We are also the licensee of United States patents relating to the
measurement of Lp(a), the measurement of bone resorption markers and our
cassette technology.
Our current products incorporate technologies which are the subject of
patents issued to, and patent applications filed by, others. We have obtained
licenses for certain of these technologies and might be required to obtain
licenses for others. There can be no assurance that we will be able to obtain
licenses for technology patented by others on commercially reasonable terms, or
at all, that we will be able to develop alternative approaches if we are unable
to obtain licenses or that our current and future licenses will be adequate for
the operation of our business. The failure to obtain such licenses or identify
and implement alternative approaches could have a material adverse effect on our
business, financial condition and results of operations.
We currently face patent infringement claims filed by Roche Diagnostics, a
subsidiary of Roche Holdings Ltd., in several individual European countries.
There can be no assurance that patent infringement claims will not be asserted
by other parties in the future, that in such event we will prevail or that we
will be able to obtain necessary licenses on reasonable terms, or at all.
Adverse determinations in any litigation could subject us to significant
liabilities and/or require us to seek licenses from third parties. If we are
unable to obtain necessary licenses or are unable to develop or implement
alternative technology, we may be unable to manufacture and
12
15
sell the affected products. Any of these outcomes could have a material adverse
effect on our business, financial condition or results of operations.
We rely substantially on trade secrets, technical know-how and continuing
invention to develop and maintain our competitive position. We work actively to
foster continuing technological innovation to maintain and protect our
competitive position, and we have taken security measures to protect our trade
secrets and periodically explore ways to further enhance trade secret security.
There can be no assurance that such measures will provide adequate protection
for our trade secrets or other proprietary information. Although we have entered
into proprietary information agreements with our employees, consultants and
advisors, there can be no assurance that these agreements will provide adequate
remedies for any breach.
GOVERNMENT REGULATION
Food and Drug Administration and Other Regulations
The manufacture and sale of our products are subject to regulation by
numerous governmental authorities, principally the United States Food and Drug
Administration (the "FDA") and corresponding state and foreign regulatory
agencies. Pursuant to the Food, Drug and Cosmetics Act of 1938, as amended (the
"FDC Act"), the FDA regulates the clinical testing, manufacture, labeling,
distribution and promotion of medical devices. Noncompliance with applicable
requirements can result in, among other things, fines, injunctions, civil
penalties, recall or seizure of products, total or partial suspension of
production, failure of the government to grant pre-market clearance or
pre-market approval for devices and criminal prosecution. The FDA also has the
authority to request repair, replacement or refund of the cost of any device
manufactured or distributed by us.
In the United States, medical devices are classified into one of three
classes, Class I, II or III, on the basis of the controls deemed by the FDA to
be necessary to reasonably ensure their safety and effectiveness. Class I
devices are subject to general controls (e.g., labeling, registration, listing
and adherence to quality systems regulations). Class II devices are subject to
general controls, pre-market notification and special controls (e.g.,
performance standards, post-market surveillance and patient registries).
Generally, Class III devices are those that must receive pre-market approval
from the FDA (e.g., life sustaining, life supporting and implantable devices, or
new devices which have not been found substantially equivalent to legally
marketed devices), and require clinical testing to assure safety and
effectiveness.
Before a new device can be introduced into the market, the manufacturer
must generally obtain marketing clearance through a pre-market notification
under Section 510(k) of the FDC Act or a pre-market approval application under
Section 515 of the FDC Act or be exempt from 510(k) requirements. Most Class I
devices are exempt from 510(k) requirements. A 510(k) clearance typically will
be granted if the submitted information establishes that the proposed device is
"substantially equivalent" to a legally marketed Class I or II medical device or
to a Class III medical device for which the FDA has not called for a pre-market
approval. A 510(k) notification must contain information to support a claim of
substantial equivalence, which may include laboratory test results or the
results of clinical studies of the device in humans. It generally takes from
four to twelve months from the date of submission to obtain 510(k) clearance,
but it may take longer. A "not substantially equivalent" determination by the
FDA, or a request for additional information, could delay the market
introduction of new products that fall into this category. For any devices that
are cleared through the 510(k) process, modifications or enhancements that could
significantly affect safety or effectiveness or constitute a major change in the
intended use of the device will require new 510(k) submissions. We obtained
510(k) clearance before marketing the L-D-X Analyzer and all existing test
cassettes in the United States.
In general, we intend to develop and market tests that will require no more
than 510(k) clearance. However, if we cannot establish that a proposed test
cassette is substantially equivalent to a legally marketed device, we will be
required to seek pre-market approval of the proposed test cassette from the FDA
through the submission of a pre-market approval application. If a future product
were to require submission of this type of application, regulatory approval of
such product would involve a much longer and more costly process than a 510(k)
clearance. We do not believe that our products under development will require
the submission of a pre-market approval application, which can be lengthy,
expensive and uncertain. A FDA review of a pre-
13
16
market approval application generally takes one to three years from the date it
is accepted for filing, but may take significantly longer.
Any products manufactured or distributed by us pursuant to FDA clearance or
approvals are subject to pervasive and continuing regulation by the FDA and
certain state agencies, including record keeping requirements and reporting of
adverse experience with the use of the device. Labeling and promotional
activities are subject to scrutiny by the FDA and, in certain circumstances, by
the Federal Trade Commission. Current FDA enforcement policy prohibits the
marketing of approved medical devices for unapproved uses.
The FDC Act regulates our quality control and manufacturing procedures by
requiring us and our contract manufacturers to demonstrate compliance with
quality systems regulations. The FDA monitors compliance with these requirements
by requiring manufacturers to register with the FDA, which subjects them to
periodic inspections. The State of California also regulates and inspects our
manufacturing facilities. We have been inspected twice by the State of
California to date and are manufacturing under an issued medical device
manufacturer's facility license from the State of California. If any violations
of our applicable regulations are noted during a FDA, European Notified Body or
State of California inspection of our manufacturing facilities or those of our
contract manufacturers, the continued marketing of our products could be
materially adversely affected.
The European Union ("EU") has promulgated rules that require that devices
such as ours receive the right to affix the CE mark, a symbol of adherence to
applicable EU directives. We have completed all the testing necessary to comply
with applicable regulations to currently be eligible for self certification and
currently have the right to affix the CE mark to our products. While we intend
to satisfy the requisite policies and procedures that will permit us to continue
to affix the CE mark to our products in the future, there can be no assurance
that we will be successful in meeting EU certification requirements. Failure to
receive the right to affix the CE mark may prohibit us from selling our products
in EU member countries and could have a material adverse effect on our business,
financial condition and results of operations.
We and our products are also subject to a variety of state and local laws
and regulations in those states or localities where our products are or will be
marketed. Any applicable state or local laws or regulations may hinder our
ability to market our products in those states or localities. For example, eight
states have regulations that impose requirements on pharmacies and/or
pharmacists that perform clinical testing, four of which have regulations that
prohibit certain pharmacy-based testing. We are also subject to numerous
federal, state and local laws relating to such matters as safe working
conditions, manufacturing practices, environmental protection, fire hazard
control and disposal of hazardous or potentially hazardous substances. There can
be no assurance that we will not be required to incur significant costs to
comply with such laws and regulations now or in the future or that such laws or
regulations will not have a material adverse effect on us.
Changes in existing requirements or adoption of new requirements or
policies could increase the cost of or otherwise adversely affect our ability to
comply with regulatory requirements. Failure to comply with regulatory
requirements could have a material adverse effect on us.
Clinical Laboratory Improvement Act Regulations
The use of our products in the United States is subject to CLIA, which
provides for federal regulation of laboratory testing, an activity also
regulated by most states. Laboratories must obtain either a registration
certificate from the Health Care Finance Administration, register with an
approved accreditation agency or obtain a state license in a state with a
federally approved license program. The CLIA regulations seek to ensure the
quality of medical testing. The three primary mechanisms to accomplish this goal
are daily quality control requirements to ensure the accuracy of laboratory
devices and procedures, proficiency testing to measure testing accuracy and
personnel standards to assure appropriate training and experience for laboratory
workers. CLIA categorizes tests as "waived," or as being "moderately complex" or
"highly complex" on the basis of specific criteria. To successfully
commercialize tests that are currently under development, we believe it will be
critical to obtain waived classification for such tests under CLIA, because CLIA
waiver allows health care providers to use the L-D-X System at a lower cost.
14
17
THIRD PARTY REIMBURSEMENT
In the United States, health care providers, such as hospitals and
physicians, that purchase products such as the L-D-X System and single-use test
cassettes generally rely on third party payors, including private health
insurance plans, federal Medicare, state Medicaid and managed care
organizations, to reimburse all or part of the cost of the procedure in which
the product is being used. Our ability to commercialize our products
successfully in the United States will depend in part on the extent to which
reimbursement for the costs of tests performed with the L-D-X System and related
treatment will be available from government health authorities, private health
insurers and other third party payors. Third party payors can affect the pricing
or the relative attractiveness of our products by regulating the maximum amount
of reimbursement provided by such payors for testing services. Reimbursement is
currently not available for certain uses of our products in particular
circumstances. For example, tests performed in the health promotion market are
generally not subject to reimbursement. Pharmacists also face blocking state
legislation in a number of states, which precludes them from accessing federally
available reimbursement codes and practices. Third party payors are increasingly
scrutinizing and challenging the prices charged for medical products and
services. Decreases in reimbursement amounts for tests performed using our
products may decrease amounts physicians and other practitioners are able to
charge patients, which in turn may adversely affect our ability to sell our
products on a profitable basis. In addition, certain health care providers are
moving toward a managed care system in which such providers contract to provide
comprehensive health care for a fixed cost per patient. Managed care providers
are attempting to control the cost of health care by authorizing fewer elective
procedures, such as the screening of blood for chronic diseases. We are unable
to predict what changes will be made in the reimbursement methods used by third
party payors. The inability of healthcare providers to obtain reimbursement from
third party payors, or changes in third party payors' policies toward
reimbursement of tests using our products, could have a material adverse effect
on our business, financial condition and results of operations. Given the
efforts to control and reduce health care costs in the United States in recent
years, there can be no assurance that currently available levels of
reimbursement will continue to be available in the future for our existing
products or products under development.
In 1991, the Health Care Finance Administration ("HCFA") adopted
regulations providing for the inclusion of capital related costs in the
prospective payment system for hospital inpatient services under which most
hospitals are reimbursed by Medicare on a per diagnosis basis at fixed rates
unrelated to actual costs, based on diagnostic related groups. Under this system
of reimbursement, equipment costs generally are not reimbursed separately, but
rather are included in a single, fixed rate, per patient reimbursement. Medicare
reform legislation requires HCFA to implement a prospective payment system for
outpatient hospital services as well. This system may also provide for a
per-patient fixed rate reimbursement for outpatient department capital costs. We
believe these regulations place more pressure on hospitals' operating margins,
causing them to limit capital expenditures. These regulations could have an
adverse effect on us if hospitals decide to defer obtaining medical equipment as
a result of any such limitation on their capital expenditures. The Medicare
legislation also requires HCFA to adopt uniform coverage and administration
policies for laboratory tests. We are unable to predict what adverse impact on
us, if any, additional government regulations, legislation or initiatives or
changes by other payors affecting reimbursement or other matters that may
influence decisions to obtain medical equipment may have.
We believe the escalating cost of medical products and services has led to
and will continue to lead to increased pressures on the health care industry,
both foreign and domestic, to reduce the cost of products and services,
including products offered by us. In addition, market acceptance of our products
in international markets is dependent, in part, on the availability of
reimbursement within prevailing health care payment systems. Reimbursement and
health care payment systems in international markets vary significantly by
country, and include both government sponsored health care and private
insurance. There can be no assurance in either domestic or foreign markets that
third party reimbursement and coverage will be available or adequate, that
current reimbursement amounts will not be decreased in the future or that future
legislation, regulation or reimbursement policies of third party payors will not
otherwise adversely affect the demand for our products or our ability to sell
our products on a profitable basis.
15
18
PRODUCT LIABILITY AND INSURANCE
The sale of our products entails risk of product liability claims. The
medical testing industry has historically been litigious, and we face financial
exposure to product liability claims if use of our products results in personal
injury. We also face the possibility that defects in the design or manufacture
of our products might necessitate a product recall. There can be no assurance
that we will not experience losses due to product liability claims or recalls in
the future. We currently maintain product liability insurance, but there can be
no assurance that the coverage limits of our insurance policies will be
adequate. Such insurance is expensive, difficult to obtain and no assurance can
be given that product liability insurance can be maintained in the future on
acceptable terms, or in sufficient amounts to protect us against losses due to
liability, or at all. An inability to maintain insurance at an acceptable cost
or to otherwise protect against potential product liability could prevent or
inhibit the continued commercialization of our products. In addition, a product
liability claim in excess of relevant insurance coverage or a product recall
could have a material adverse effect on our business, financial condition and
results of operations.
The services performed by our WellCheck business entail risk of
professional liability and cyber liability claims. The medical testing industry
has historically been litigious, and we face financial exposure to professional
liability, malpractice and cyber liability claims if services provided by our
employees and our products result in personal injury. There can be no assurance
that we will not experience losses due to such claims in the future. We
currently maintain professional liability and cyber liability insurance, but
there can be no assurance that the coverage limits of our insurance policies
will be adequate. Such insurance is expensive, difficult to obtain and no
assurance can be given that such insurance can be maintained in the future on
acceptable terms, or in sufficient amounts to protect us against losses due to
liability, or at all. An inability to maintain insurance at an acceptable cost
or to otherwise protect against potential claims could prevent or inhibit the
continued commercialization of our products and services. In addition, a claim
in excess of relevant insurance coverage could have a material adverse effect on
our business, financial condition and results of operations.
We have liability insurance covering our property and operations with
coverage, deductible amounts and exclusions, which we believe are customary for
companies of our size in our industry. However, there can be no assurance that
our current insurance coverage is adequate or that we will be able to maintain
insurance at an acceptable cost or otherwise to protect against liability.
EMPLOYEES
As of March 30, 2001, we employed 221 full-time, regular associates,
including 136 in our Diagnostic Products business, 61 in our WellCheck business,
eight in our WellCheck.com business and 16 in corporate administration. There
were 78 associates in sales, marketing and administration, 84 associates in
manufacturing, 43 associates in field testing and 16 associates devoted to
research and development. None of the associates is covered by a collective
bargaining agreement, and management considers relations with employees to be
excellent.
16
19
EXECUTIVE OFFICERS
The names, ages and positions of our current executive officers are as
follows:
NAME AGE POSITION
---- --- --------
Warren E. Pinckert II........ 57 President, Chief Executive Officer and Director
William W. Burke............. 42 Vice President of Finance, Chief Financial Officer,
Treasurer and Secretary
Robert J. Dominici........... 57 Executive Vice President and Chief Operating Officer
(Diagnostic Products)
David A. Gyorke.............. 41 Vice President of Operations (Diagnostic Products)
Timothy I. Still............. 35 Vice President of Sales and Marketing
(Diagnostic Products)
Kevin R. Stromberg........... 39 Vice President of Engineering (WellCheck)
Terry L. Wassmann............ 54 Vice President of Human Resources
Thomas E. Worthy............. 59 Vice President of Development and Regulatory Affairs
(Diagnostic Products)
Warren E. Pinckert II has served as our President, Chief Executive Officer
and a Director since June 1993. Mr. Pinckert served as Executive Vice President
of Operations of Cholestech from 1991 to June 1993, and as Chief Financial
Officer and Vice President of Business Development of Cholestech from 1989 to
June 1993. Mr. Pinckert also served as Secretary of Cholestech from 1989 to
January 1997. Before joining Cholestech, Mr. Pinckert was Chief Financial
Officer of Sunrise Medical Inc., an international durable medical products
manufacturer, from 1983 to 1989. Mr. Pinckert also serves on the board of
directors of PacifiCare Health Systems, Inc., a managed care organization. Mr.
Pinckert holds a Bachelor of Science degree in Accounting and a Masters of
Business Administration degree from the University of Southern California and is
a certified public accountant.
William W. Burke has served as Vice President of Finance, Chief Financial
Officer, Treasurer and Secretary since joining our company in April 2001. From
August 1998 to March 2001, Mr. Burke was a Managing Director in Bear, Stearns &
Co. Inc.'s investment banking department where he was responsible for broadening
Bear Stearns' investment banking franchise in the southwest in several
industries, including healthcare. As a Managing Director in Everen Securities,
Inc.'s ("Everen's") investment banking group from May 1991 to May 1995 and
January 1998 to August 1998, he specialized in advising emerging growth medical
technology companies. From May 1995 to January 1998, he served as Managing
Director and Director of Healthcare Investment Banking for Principal Financial
Securities, Inc., which was acquired by Everen in January 1998. Mr. Burke holds
a Bachelor of Business Administration degree in Finance from the University of
Texas at Austin and a Masters of Business Administration degree from the
University of Pennsylvania's Wharton Graduate Business School.
Robert J. Dominici joined our company as Executive Vice President of
Marketing and Sales in August 1998. In September 1999, Mr. Dominici was promoted
to Chief Operating Officer of our Diagnostic Products business. From January
1997 to May 1998, Mr. Dominici served as Senior Vice President/General Manager
Corporate Accounts for Boehringer Mannheim Corporation, a healthcare diagnostic
products company. Before his position as Senior Vice President, Corporate
Accounts, Mr. Dominici held other positions within Boehringer Mannheim including
Vice President Marketing, Sales and Services and President of the Laboratory
Systems Division. From February 1992 to December 1996, he was President and
Chief Executive Officer of Microgenics Corporation, a wholly owned subsidiary of
Boehringer Mannheim. Mr. Dominici holds a Bachelor of Science degree in Biology
and Chemistry from Otterbein College.
David A. Gyorke was recently promoted to the position of Vice President of
Operations for our Diagnostic Products business in July 2000. Mr. Gyorke
previously served as our Director of the Operations' Engineering Groups. Before
joining Cholestech in January 1999, Mr. Gyorke was the Manufacturing &
Technology Engineering Manager of Target Therapeutics, a neuro medical device
manufacturer and a division of the Boston Scientific Corporation. During his
tenure with Target, Mr. Gyorke was responsible for various product lines plus
implementing new processing technologies for the neuro catheter, balloon,
guidewire and embolic
17
20
coil production lines. Mr. Gyorke's experience also includes positions with
Bio-Rad Laboratories, Diasonics Ultrasound Inc. and defense contractors
ArgoSystems, Inc. and Raytheon Company. His engineering internship was with
McDonnell Douglas. Mr. Gyorke holds a Bachelor of Science degree in Industrial
Engineering from the California Polytechnic State University, San Luis Obispo.
Timothy I. Still is Vice President of Sales and Marketing and Sales for our
Diagnostic Products business. Mr. Still joined Cholestech as the Senior Director
of Marketing in December 1997. Before joining Cholestech, Mr. Still was a
Director of Global Marketing and Business Development for Boehringer Mannheim
Corporation. During his tenure with Boehringer Mannheim from August 1992 to
November 1997, Mr. Still was responsible for the global sales and marketing of
the CEDIA immunoassay product line. Before joining Boehringer Mannheim, Mr.
Still was a Product Manager with Bio-Rad Laboratories from June 1992 to August
1992 where he was responsible for the marketing of various immunoassay reagents
and instrumentation. Mr. Still holds a Bachelor of Science degree in Biological
Sciences from the University of California at Davis and a Masters of Business
Administration degree in Marketing and Entrepreneurship from the University of
Southern California.
Kevin R. Stromberg is Vice President of Engineering and Operations for our
WellCheck business. Mr. Stromberg was previously Vice President of Engineering
of WellCheck.com from April 2000 to January 2001. Before joining Cholestech, he
was Director of Information technology for Bay Alarm Company from February 1998
to April 2000. Before Bay Alarm, Mr. Stromberg held the position of Engineering
Manager from January 1996 to February 1998 for Sun Microsystems, Inc. From 1994
to 1996, he held several positions at Shared Medical Systems' Allegra Division.
Additionally, he held positions from 1992 to 1994 with Interactive Development
Environments, Inc. and Wollongong Software companies and operated his own
consulting business. Mr. Stromberg holds a Bachelor of Science degree in
Computer Information Systems from the University of San Francisco.
Terry L. Wassmann joined our company in March 2000 as Vice President of
Human Resources. Before joining Cholestech, Ms. Wassmann served as Staff
Relations Manager with Robert Half International from July 1999 to March 2000.
From February 1986 until December 1999, Ms. Wassmann was employed by Boehringer
Mannheim where She held numerous positions within the Human Resources
department, including the Director of Human Resources of the Indiana and
California based Diagnostics Division.
Dr. Thomas E. Worthy is Vice President, Development and Regulatory Affairs
for our Diagnostic Products business. He was previously our Director of
Technical Affairs. Before joining Cholestech, Dr. Worthy held Director of
Research and Development positions at Microgenics Corporation from February 1988
to April 1998, a division of Boehringer Mannheim Corporation, and at MetPath,
Inc. from May 1981 to February 1988. He holds a Doctor of Philosophy degree in
Radiation Biology from the University of Tennessee, a Master of Science degree
in Microbiology from Northern Illinois University and a Bachelor of Arts degree
in Biology from Albion College.
ITEM 2. PROPERTIES
We lease 47,000 square feet in Hayward, California and 5,100 square feet in
Oakland, California. Our facilities contain approximately 8,000 square feet of
laboratory space and 10,000 square feet of manufacturing space with the balance
devoted to marketing and administrative and common areas. Our original lease on
the main Hayward facility expired on March 31, 2000 and we have agreed to renew
the lease for two years at 90% of the then current market rate. We believe this
facility is adequate to meet our requirements through the expiration of our
lease. Additionally, we are in negotiations to extend the lease for four to
eight years for our current headquarters location and anticipate finalizing this
lease in mid 2001. We also rent 3,000 square feet on a month-to-month basis in
Hammond, Louisiana.
ITEM 3. LEGAL PROCEEDINGS
On February 5, 1999, a complaint entitled Ree v. Pinckert, et al., No.
C99-0562 (PJH) was filed in the United States District Court for the Northern
District of California. The action is a putative class action and the complaint
alleges that our company and certain of its current and former officers violated
the federal
18
21
securities laws by making false and misleading statements concerning our company
and its business during the period of June 28, 1996 through June 25, 1998. On
June 14, 2001, we executed an agreement in principle with plaintiffs to resolve
this matter for a payment $3 million by our insurance carrier. We recorded a
$1.3 million charge during the year ended March 30, 2001 for legal fees and
insurance costs related to resolving this matter. The settlement is contingent
on Court approval.
On December 23, 1999, a complaint requesting an injunction, No. ES-580-199,
was filed in Zug, Switzerland by Roche Diagnostics seeking a cease and desist
order barring us and two of our distributors from distributing HDL assay
single-use test cassettes in Switzerland. The complaint alleges that we violated
a Roche European patent for HDL. We have filed our response to the complaint. On
July 11, 2000 the court denied the plaintiff's request for an injunction and
ordered them to pay a portion of our legal fees. The plaintiff has appealed the
court ruling. At this point in time no schedule has been set regarding
additional court activity. There can be no assurance as to wether the plaintiffs
will take any additional action, or any additional action be resolved in our
favor.
In September 2000, we were served a complaint, No. Ei/Ti ROCH 04002, filed
in Vienna, Austria by Roche Diagnostics, a subsidiary of Roche Holdings, Ltd.,
seeking a cease and desist order barring us and one of our distributors from
distributing HDL assay single-use test cassettes in Austria. The complaint
alleges that we violated a Roche European patent for HDL. At this point, no
schedule has been set regarding court activity. There can be no assurance as to
whether the plaintiffs will take any additional action or whether any additional
action will be resolved in our favor.
Additionally, in January 2000, a complaint, No. 4 O 4/00, was filed in the
District Court, Dusseldorf, Germany by Roche Diagnostics against us and two of
our distributors seeking a cease and desist order barring the distributors from
shipping HDL single-use test cassettes into Germany. The complaint alleges we
and our distributors violated a Roche German priority patent for HDL by selling
our single-use test cassette containing a HDL assay. The court has requested
additional information be submitted by both parties, but has not made any ruling
or set additional court dates. We believe the suit is without merit and intend
to defend the case vigorously. Therefore, we do not believe that the outcome of
this matter will result in a material adverse effect. However, there can be no
assurance that the lawsuit will be resolved in our favor.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None.
19
22
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
Our common stock is quoted on the NASDAQ National Market under the symbol
"CTEC." On March 30, 2001, the last reported sale price for our common stock on
the NASDAQ National Market was $4.81 per share. The following table sets forth
the quarterly high and low trading prices for our common stock.
HIGH LOW
------ -----
FISCAL YEAR 2000
First Quarter............................................... $ 2.97 $1.94
Second Quarter.............................................. 8.38 2.25
Third Quarter............................................... 7.50 5.63
Fourth Quarter.............................................. 10.44 5.19
FISCAL YEAR 2001
First Quarter............................................... $ 8.97 $6.00
Second Quarter.............................................. 8.00 6.38
Third Quarter............................................... 7.50 4.81
Fourth Quarter.............................................. 6.59 3.69
As of March 30, 2001 there were approximately 211 holders of record of our
common stock.
We have never paid cash dividends on our common stock and do not anticipate
paying cash dividends in the foreseeable future.
20
23
ITEM 6. SELECTED CONSOLIDATED FINANCIAL DATA
The following selected consolidated financial data should be read in
conjunction with our consolidated financial statements and notes thereto and
"Management's Discussion and Analysis of Financial Condition and Results of
Operations". The following selected consolidated statement of operations data
for the fiscal years ended March 30, 2001, March 31, 2000 and March 26,1999 and
the selected consolidated balance sheet data as of March 30, 2001 and March 31,
2000 are derived from, and qualified by reference to, the audited consolidated
financial statements included elsewhere in this Annual Report on Form 10-K. The
selected consolidated statement of operations data for the fiscal years ended
March 27, 1998 and March 28, 1997 and the consolidated balance sheet data as of
March 26, 1999, March 27, 1998 and March 28, 1997 have been derived from our
audited consolidated financial statements not included herein. These historical
results are not necessarily indicative of the results of operations to be
expected from any future period.
YEAR ENDED MARCH 31,(1)
-----------------------------------------------
2001 2000 1999 1998 1997
------- ------- ------- ------- -------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
CONSOLIDATED STATEMENT OF OPERATIONS DATA:
Revenue(2)..................................... $37,003 $27,549 $22,032 $21,664 $12,861
Cost of revenue(2)............................. 15,280 11,211 10,252 10,513 6,957
------- ------- ------- ------- -------
Gross profit................................... 21,723 16,338 11,780 11,151 5,904
------- ------- ------- ------- -------
Operating expenses:
Sales and marketing......................... 11,388 7,032 6,606 5,380 4,108
Research and development.................... 2,586 3,021 2,703 2,224 1,341
Website and other related costs............. 1,952 -- -- -- --
General and administrative.................. 5,079 3,510 2,381 2,087 1,537
Goodwill amortization....................... 709 100 -- -- --
Legal and other related..................... 1,312 219 826 -- --
Impairment charge........................... 1,958 -- -- -- --
------- ------- ------- ------- -------
Total operating expenses............... 24,984 13,882 12,516 9,691 6,986
------- ------- ------- ------- -------
Income (loss) from operations.................. (3,261) 2,456 (736) 1,460 (1,082)
Interest and other income, net................. 655 805 663 569 273
------- ------- ------- ------- -------
Income (loss) before taxes..................... (2,606) 3,261 (73) 2,029 (809)
Provision for income taxes..................... -- 129 -- 41 --
------- ------- ------- ------- -------
Net income (loss).............................. $(2,606) $ 3,132 $ (73) $ 1,988 $ (809)
======= ======= ======= ======= =======
Net income (loss) per share:
Basic....................................... $ (.22) $ 0.27 $ (0.01) $ 0.18 $ (0.08)
======= ======= ======= ======= =======
Diluted..................................... $ (.22) $ 0.26 $ (0.01) $ 0.17 $ (0.08)
======= ======= ======= ======= =======
Shares used to compute net income (loss) per
share:(3)
Basic....................................... 12,046 11,724 11,484 11,289 10,382
======= ======= ======= ======= =======
Diluted..................................... 12,046 11,920 11,484 11,905 10,382
======= ======= ======= ======= =======
MARCH 31,(1)
----------------------------------------------------
2001 2000 1999 1998 1997
-------- -------- -------- -------- --------
(IN THOUSANDS)
CONSOLIDATED BALANCE SHEET DATA:
Cash, cash equivalents and marketable
securities............................. $ 12,365 $ 13,741 $ 11,427 $ 14,751 $ 14,009
Working capital........................... 10,254 11,522 13,342 17,662 16,124
Total assets.............................. 30,742 32,218 24,283 25,788 21,087
Accumulated deficit....................... (48,030) (45,424) (48,556) (48,483) (50,471)
Shareholders' equity...................... 24,858 26,476 21,769 21,446 18,703
21
24
---------------
(1) Our fiscal year is a 52-53 week period ending on the last Friday in March.
All fiscal years referenced in this Annual Report on Form 10-K consisted of
52 weeks, except fiscal 2000, which consisted of 53 weeks. For convenience,
we have indicated in this Annual Report on Form 10-K that our fiscal year
ends on March 31 and refer to the fiscal year ending March 30, 2001 as
fiscal 2001, the fiscal year ending March 31, 2000 as fiscal 2000, the
fiscal year ending March 26, 1999 as fiscal 1999, the fiscal year ending
March 27, 1998 as fiscal 1998 and the fiscal year ending March 28, 1997 as
fiscal 1997.
(2) Revenue and costs of revenue figures have been revised as a result of the
retroactive adoption of EITF 00-10 "Accounting for Shipping and Handling
Fees and Costs".
(3) See Note 1 of Notes to Consolidated Financial Statements for an explanation
of the shares used to compute net income (loss) per share.
22
25
ITEM 7: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
Certain statements in this "Management's Discussion and Analysis of
Financial Condition and Results of Operations" are forward looking statements.
These statements relate to future events or our future financial performance and
involve known and unknown risks, uncertainties and other factors that may cause
our or our industry's actual results, levels of activity, performance or
achievements to be materially different from any future results, levels of
activity, performance or achievements expressed or implied by the forward
looking statements. These risks and other factors include those listed under
"Risk Factors" and elsewhere in this Annual Report on Form 10-K. In some cases,
you can identify forward-looking statements by terminology such as "may",
"will", "should", "expect", "plan", "anticipate", "believe", "estimate",
"predict", "potential", "continue" or the negative of these terms or other
comparable terminology. These statements are only predictions. Actual events or
results may differ materially. In evaluating these statements, you should
specifically consider various factors, including the risks outlined under
"Factors Affecting Future Operating Results". These factors may cause our actual
results to differ materially from any forward looking statement.
Although we believe the expectations reflected in the forward looking
statements are reasonable, we cannot guarantee future results, levels of
activity, performance or achievements. Moreover, neither we nor any other person
assumes responsibility for the accuracy and completeness of these forward
looking statements. We are under no duty to update any of the forward looking
statements after the date of this Annual Report on Form 10-K to conform our
prior statements to actual results.
OVERVIEW
In the past fiscal year, we engaged in three business segments:
- Diagnostic Products -- which develops, manufactures and markets our
L-D-X(R) System (the "L-D-X System") which performs near-patient
diagnostic tests that assist in assessing the risk of certain
cholesterol-related diseases, certain liver diseases, and in the
monitoring of therapy to treat that diseases.
- WellCheck -- which conducts consumer testing within the United States
that assesses the risk of certain cholesterol-related and other diseases
and assists in the monitoring of therapy to treat those diseases.
- WellCheck.com -- which provides interactive tools to consumers through
the Internet to better assess the risk of certain cholesterol-related and
other diseases and to monitor and motivate personal health management of
those diseases.
Diagnostic Products currently manufactures and markets the L-D-X System,
including the L-D-X Analyzer and a variety of single-use test cassettes, in the
United States and internationally. The L-D-X System allows health care providers
to perform individual tests or combinations of tests with a single drop of blood
from a fingerstick within five minutes. Our current products measure and monitor
blood cholesterol, related lipids, glucose and liver function, and are used to
test patients at risk of or suffering from heart disease, diabetes or liver
disease.
WellCheck currently provides cholesterol and related testing services and
education to the general public using the L-D-X System and creates opportunities
for sales of test cassettes manufactured by our Diagnostic Products business.
WellCheck's professionals provide high quality services and offer test event
expertise to both event sponsors and consumers. As part of our testing services,
we utilize our proprietary TEAMS technology which automates registration, data
acquisition and information management at promotional, corporate wellness and
other consumer testing events and provides consumers with a personalized risk
assessment for heart disease. Substantially all of WellCheck's revenue is
derived from promotional programs with major pharmaceutical companies marketing
lipid-lowering statin drugs. We believe an opportunity exists to further expand
our testing services business in the promotional, corporate wellness, retail
markets and other convenient venues which broaden consumer access to testing
while assisting consumer product companies, such as pharmaceutical companies, in
customer acquisition. Our goal is to develop the first nationwide consumer
testing services company for chronic diseases.
23
26
We launched WellCheck.com operations in October 1999 to develop website
content and TEAMS technology to provide consumers with interactive tools to
learn about and manage cholesterol-related diseases. Based on our determination
that adequate sponsor funding for a retail-oriented, chronic disease management
model roll out was unavailable at present, we refocused on expanding our
activities in the promotional and corporate wellness market. As a result, our
WellCheck.com business unit and its consumer-oriented website have been
repositioned as a technology support tool for our WellCheck business. In the
fourth quarter of fiscal 2001, we recorded a non-cash, non-recurring charge of
$1.96 million to reflect the impairment of certain intangible assets associated
with the development of WellCheck.com's website and database.
More recently we merged WellCheck.com into WellCheck. We intend to operate
and manage WellCheck and WellCheck.com as one business segment in fiscal 2002
and beyond.
RESULTS OF OPERATIONS
YEARS ENDED MARCH 30, 2001 AND MARCH 31, 2000
Revenue. Our total revenue increased 34.3% to $37.0 million in fiscal 2001
from $27.5 million in fiscal 2000. Diagnostic Products represented 87.8% of
total revenue in fiscal 2001 and 98.0% of total revenue in fiscal 2000.
International revenue represented 17.4% of our total revenue in fiscal
2001, compared to 17.6% in fiscal 2000. In fiscal 2001 all international revenue
related to the Diagnostic Products business unit.
Segment performance was as follows:
- Diagnostic Products revenue increased 20.3% to $32.5 million in fiscal
2001 from $27.0 million in fiscal 2000. The increase in revenue mainly
reflected an 18.1% increase in unit sales of single-use test cassettes.
The growth was in the physician office laboratory, health promotion and
international markets. Additionally, unit sales of the L-D-X System
increased by 42.9%. L-D-X sales increased in all markets, other than
pharmacy.
- WellCheck revenue increased 706.7% to $4.4 million in fiscal 2001 from
$549,000 in fiscal 2000. The increase in revenue reflected the fact that
WellCheck was only included in our results of operations during the last
two months of fiscal 2000.
- WellCheck.com revenue increased to $85,000 in fiscal 2001 from no revenue
in fiscal 2000.
Cost of Revenue. Our cost of revenue increased 36.3% to $15.3 million in
fiscal 2001 from $11.2 million in fiscal 2000. Gross margins were 58.7% in
fiscal 2001 and 59.3% in fiscal 2000. Diagnostic Products accounted for 92.0% of
our cost of products sold and the other 8% related to service revenue from
WellCheck and WellCheck.com in fiscal 2001. Diagnostic Products accounted for
98.6% of our costs of products sold and 1.4% related to service revenue in
fiscal 2000.
Segment performance was as follows:
- Diagnostic Products cost of revenue includes direct labor, direct
material, overhead and royalties. Cost of revenue increased 27.1% to
$14.1 million in fiscal 2001 from $11.1 million in fiscal 2000. The
increase was primarily related to the higher unit sales of single-use
test cassettes, and costs of validations and testing of our new
manufacturing line for cassettes which is currently in preproduction
validation. Gross margin was 56.7% in fiscal 2001 and 59.1% in fiscal
2000. The gross margin decline was primarily attributable to spending
related to prepare the new production equipment for full operation during
July 2001.
We have licensed certain technology used in the manufacturing of certain of
our products. A related agreement, which expires in 2006, requires us to
pay a royalty of 2.0% on net sales of single use test cassettes. Total
royalty expense was $490,000 in fiscal 2001 and $456,000 in fiscal 2000 and
such amounts were charged to cost of product revenue.
24
27
- WellCheck cost of revenue includes reimbursed travel expenses, laboratory
services, medical waste disposal and the cost of medical testing
equipment and supplies. Costs of product provided by the Diagnostic
Products business are eliminated on consolidation. Total cost of revenue
was $1.2 million in fiscal 2001 and $155,000 for the two months of
operations in fiscal 2000.
- WellCheck.com does not have any costs associated with its revenue. Costs
associated with the maintenance of TEAMS and the website are included in
website and related costs in the consolidated statement of operations.
Operating Expenses
Sales and Marketing. Our sales and marketing expense includes salaries,
commissions, bonuses, expenses for outside services related to marketing
programs and travel expenses. Sales and marketing expenses increased 61.9% to
$11.4 million in fiscal 2001 from $7.0 million in fiscal 2000. Sales and
marketing expenses increased to 30.8% of revenue in fiscal 2001 from 25.5% in
fiscal 2000. Diagnostic Products accounted for 70% of sales and marketing
expenses for fiscal 2001 and 97.2% of sales and marketing expenses for fiscal
2000.
Sales and marketing expense in each of our segments was as follows:
- Diagnostic Products sales and marketing expense increased 16.6% to $8.0
million in fiscal 2001 from $6.8 million in fiscal 2000. The increase
relates to increased advertising, trade show and promotional costs. Sales
and marketing expense decreased to 24.5% of revenue in fiscal 2001 from
25.3% of revenue in fiscal 2000.
- WellCheck sales and marketing expense increased significantly to $2.7
million in fiscal 2001 from $200,000 in fiscal 2000. This increase
reflects the fact that WellCheck was only included in our results of
operations for last two months of fiscal 2000.
- WellCheck.com sales and marketing expense was $683,000 in fiscal 2001.
During fiscal 2000 there was no sales and marketing expense as this
business was focused on developing the concept and structure of the
website and had not started contacting potential customers for
sponsorship or advertising related to the business.
Research and Development. Our research and development expense includes
salaries, bonuses, and expenses for outside services, supplies and amortization
of capital equipment. Research and development expense decreased 14.4% to $2.6
million in fiscal 2001 from $3.0 million in fiscal 2000. Research and
development expenses as a percentage of revenue decreased to 7.0% in fiscal 2001
compared to 11.0% in fiscal 2000. Diagnostic Products accounted for 84.9% of
research and development expense in fiscal 2001 and 79.8% of research and
development expense in fiscal 2000. WellCheck.com incurred 15.1% of the research
and development expense reported in fiscal 2001.
Research and development expense in each of our segments was as follows:
- Diagnostic Products research and development expense decreased 9.0% to
$2.2 million in fiscal 2001 from $2.4 million in fiscal 2000. This
reduction was mainly attributable to reduced head count and related
expenses as the ALT single-use test cassette approached development
completion. Research and development expense as a percentage of revenue
decreased to 6.8% in fiscal 2001 compared to 8.9% in fiscal 2000.
- WellCheck incurred no research and development expense in fiscal 2001.
- WellCheck.com research and development expense was $392,000 in fiscal
2001, net of $874,000 of certain capitalized website costs and $286,000
of capitalized TEAMS software development costs.
General and Administrative. Our general and administrative expense includes
salaries and benefits, as well as expenses for outside professional services
including information services, legal fees, accounting, our medical advisory
board and costs associated with our board of directors. General and
administrative expense increased by 44.7% to $5.1 million in fiscal 2001 from
$3.5 million in fiscal 2000. General and administrative expense increased to
13.7% of revenue in fiscal 2001 from 12.7% in fiscal 2000. Diagnostic Products
25
28
represented 52.1% of general and administrative expense in fiscal 2001 and 67.5%
of general and administrative expenses in fiscal 2000. WellCheck.com accounted
for 25.4% and WellCheck accounted for 22.5% of the general and administrative
expense in fiscal 2001.
General and administrative expense in each of our segments was as follows:
- Diagnostic Products general and administrative expense increased by 11.5%
or $272,000 to $2.6 million in fiscal 2001 from $2.4 million in fiscal
2000. General and administrative expense decreased to 8.1% of revenue in
fiscal 2001, compared to 8.8% in fiscal 2000. The increase relates to the
wages, benefits and other costs for the segment's Chief Operating Officer
and staff. This position was not created until the third quarter of
fiscal 2000.
- WellCheck general and administrative expense was $1.1 million in fiscal
2001 compared to $245,000 in fiscal 2000. In fiscal 2001 general and
administrative expense was 25.8% of revenue. The increase reflects that
WellCheck was only included in our results of operations for the last two
months of fiscal 2000.
- WellCheck.com general and administrative expense was $1.3 million in
fiscal 2001 compared to $896,000 in fiscal 2000. The increase was due to
WellCheck.com being included in our results of operations for the last
six months of fiscal 2000.
Goodwill Amortization. Goodwill amortization expense includes the
amortization of capitalized costs associated with the purchase of Health Net in
January 2000. Amortization expense increased 609.0% to $709,000 in fiscal 2001
from $100,000 in fiscal 2000. All costs were associated with the WellCheck
business.
Legal and Other Related. Our legal and related expense includes
professional consulting fees, court related costs, and other fees relating to
litigation. Legal and related expense increased 499% to $1.3 million in fiscal
2001 from $219,000 in fiscal 2000. All costs incurred in fiscal 2001 and fiscal
2000 relate to the same class action lawsuit for which a settlement was reached
in June 2001.
Impairment Charge. In the fourth quarter of fiscal 2001 we recorded
impairment expense of $1.96 million relating to certain capitalized website and
database development costs. As we have been unable to generate significant
revenues from our website and related database, the determination was that the
carrying value of these costs exceeded their estimated future cash flows. There
was no impairment expense during fiscal 2000.
Interest and Other Income, Net. Interest income reflects income from the
investment of cash balances and marketable securities, net of expenses. Interest
income decreased 18.6% to $655,000 in fiscal 2001 from $805,000 in fiscal 2000.
This decrease was primarily the result of reduced cash equivalents and
marketable securities resulting from investments in our WellCheck and
WellCheck.com operations.
Income Taxes. We have significant net operating loss ("NOLs") and tax
credit carryforwards. There was no provision for income taxes in fiscal 2001 due
to the net operating loss. The $129,000 provision for income taxes in fiscal
2000 represented the estimated federal and state alternative minimum taxes
payable, reduced for the use of NOLs and tax credit carryforwards. Management
expects to use NOLs and other tax carryforward amounts to the extent taxable
income is earned in fiscal 2002 and beyond. Therefore, our effective tax rate
should continue to be substantially less than the applicable statutory rates. As
of March 30, 2001, we had NOL carryforwards of $44.3 million available to reduce
future taxable income for federal income tax purposes and NOL carryforwards of
$3.2 million available to reduce taxable income for state income tax purposes.
Additionally, we had research and development and other tax credit carryforwards
available to reduce income taxes for federal income tax purposes of $1.9 million
and research and development and other tax credit carryforwards available to
reduce income taxes for state income tax purposes of $768,000. We have
historically experienced significant operating losses and operate in an industry
subject to rapid technological changes. Therefore, management believes there is
sufficient uncertainty regarding our ability to generate future taxable income
and use these NOLs and tax credit carryforwards such that a full valuation
allowance for deferred tax assets was required at March 30, 2001.
26
29
As a result of a change in our ownership which has occurred, there are
annual limitations of approximately $1.5 million for federal and state income
tax purposes on the combined use of federal NOLs and federal and state tax
credit carryforwards.
YEARS ENDED MARCH 31, 2000 AND MARCH 26, 1999
Revenue. Our total revenue increased 25.1% to $27.5 million in fiscal 2000
from $22.0 million in fiscal 1999. Diagnostic Products represented 98.5% of our
total revenue in fiscal 2000 and 100% in fiscal 1999.
International revenue represented 17.6% of our total revenue in fiscal
2000, compared to 12.9% in fiscal 1999. In fiscal 2000 all international revenue
related to the Diagnostic Products business unit.
Segment performance was as follows:
- Diagnostic Products revenue increased 22.5% to $27.0 million in fiscal
2000 from $22.0 million in fiscal 1999. The increase in revenue mainly
reflected increased unit sales of single-use test cassettes in the
physician office laboratory, health promotion and international markets.
Unit sales of the L-D-X System declined in all domestic markets, other
than international.
- WellCheck revenue totaled $549,000 in fiscal 2000. All revenue since
acquisition was earned during the last two fiscal months of fiscal 2000.
- WellCheck.com did not generate any revenue in fiscal 2000.
Cost of Revenue. Our cost of revenue increased 9.3% to $11.2 million in
fiscal 2000 from $10.3 million in fiscal 1999. Gross margins were 59.3% in
fiscal 2000 and 53.5% in fiscal 1999. Diagnostic Products accounted for 98.6% of
our cost of products sold in fiscal 2000 and 100% in fiscal 1999.
Segment performance was as follows:
- Diagnostic Products cost of revenue includes direct labor, direct
material, overhead and royalties. Cost of revenue increased 7.8% to $11.1
million in fiscal 2000 from $10.3 million in fiscal 1999. The increase in
cost relating to the higher unit sales of single-use test cassettes was
offset by reductions in indirect factory spending. Gross margins were
59.1% in fiscal 2000 and 53.5% in fiscal 1999. The gross margin
improvement was primarily attributable to stronger spending controls.
We have licensed certain technology used in the manufacturing of certain of
our products. A related agreement, which expires in 2006, requires us to
pay a royalty of 2.0% on net sales of the applicable products. Total
royalty expense was $456,000 in fiscal 2000 and $379,000 in fiscal 1999,
and such amounts were charged to cost of revenue.
- WellCheck cost of revenue includes reimbursed travel expenses, laboratory
services, medical waste disposal and the cost of medical testing
equipment and supplies. Costs of product provided by the Diagnostic
Products business are eliminated on consolidation. For the two months of
operations in fiscal 2000, total cost of revenue was $155,000.
- WellCheck.com cost of revenue will include costs related to the
development and expansion of our two Internet-related software tools,
TEAMS and WellCheck.com and amortization of capitalized website
development costs.
Operating Expenses
Sales and Marketing. Our sales and marketing expense includes salaries,
commissions, bonuses, expenses for outside services related to marketing
programs and travel expenses. Sales and marketing expenses increased 6.4% to
$7.0 million in fiscal 2000 from $6.6 million in fiscal 1999. Sales and
marketing expenses decreased to 25.5% of revenue in fiscal 2000 from 30.0% in
fiscal 1999. Diagnostic Products accounted for 97.2% of sales and marketing
expenses for fiscal 2000 and 100% for fiscal 1999.
27
30
Sales and marketing expense in each of our segments was as follows:
- Diagnostic Products sales and marketing expense increased 3.3% to $6.8
million in fiscal 2000 from $6.6 million in fiscal 1999. The increase can
be attributed primarily to the increased use of professional outside
services. Sales and marketing expense decreased to 25.3% of revenue in
fiscal 2000 from 30.0% of revenue in fiscal 1999. This change was
partially impacted by the transfer of costs related to the former
Executive Vice President of Marketing and Sales, who became the Chief
Operating Officer of Diagnostic Products in October 1999 with associated
costs thereafter reported on the general and administrative line of the
Statement of Operations.
- WellCheck sales and marketing expense was $200,000 in fiscal 2000. This
business unit only operated during the last two months of fiscal 2000.
- WellCheck.com incurred no sales and marketing expense in fiscal 2000 as
this business was still in the development stage.
Research and Development. Our research and development expense includes
salaries, bonuses, expenses for outside services, supplies and amortization of
capital equipment. Research and development expense increased 11.8% to $3.0
million in fiscal 2000 from $2.7 million in fiscal 1999. Research and
development expenses as a percentage of revenue decreased to 11.0% in fiscal
2000 compared to 12.3% in fiscal 1999. Diagnostics Products accounted for 79.8%
of research and development expense in fiscal 2000 and 100% in fiscal 1999.
WellCheck.com incurred 20.2% of the research and development cost reported in
fiscal 2000.
Research and development expense in each of our segments was as follows:
- Diagnostic Products research and development expense decreased 10.8% to
$2.4 million in fiscal 2000 from $2.7 million in fiscal 1999. This
reduction was mainly attributable to reduced head count and related
expenses as the ALT single-use test cassette approached development
completion. Research and development expense as a percentage of revenue
decreased to 8.9% in fiscal 2000 compared to 12.3% in fiscal 1999.
- WellCheck incurred no research and development costs in fiscal 2000.
- WellCheck.com research and development expense was $609,000 in fiscal
2000 net of $2.0 million of capitalized website development costs.
Activity occurred in the last six months of the year and was attributed
to the design and development of the WellCheck.com website and TEAMS.
General and Administrative. Our general and administrative expense includes
compensation and benefits, as well as expenses for outside professional services
including information services, legal, accounting, our medical advisory board
and costs associated with our board of directors. General and administrative
expense increased by 47.4% to $3.5 million in fiscal 2000 from $2.4 million in
fiscal 1999. General and administrative expense increased to 12.7% of revenue in
fiscal 2000 from 10.8% in fiscal 1999. Diagnostics Products represented 67.5% of
general and administrative expense in fiscal 2000 and 100% in fiscal 1999.
WellCheck.com accounted for 25.5% and WellCheck accounted for 7% of general and
administrative expense in fiscal 2000.
General and administrative expense in each of our segments was as follows:
- Diagnostic Products general and administrative expense remained
relatively constant at $2.4 million in both fiscal 2000 and fiscal 1999,
despite the addition of a Chief Operating Officer position. The addition
of the Chief Operating Officer position and related expenses were offset
by the partial allocation of corporate expenses to each of the other two
business segments. General and administrative expense decreased to 8.8%
of revenue in fiscal 2000, compared to 10.8% in fiscal 1999.
- WellCheck general and administrative expense was $245,000 during the two
months of operations since acquisition during fiscal 2000. In fiscal 2000
general and administrative expense was 44.6% of revenue.
28
31
- WellCheck.com general and administrative expense was $896,000 during the
final six months of fiscal 2000.
Goodwill Amortization. Goodwill amortization expense includes the costs
relating to the amortization of capitalized costs associated with the purchase
of Health Net in January 2000. In fiscal 2000 we recorded goodwill amortization
of $100,000. Our WellCheck business unit accounted for 100% of the expense.
Legal and Other Related. Our legal and related expense includes
professional consulting fees, court related costs, and other fees relating to
litigation. Legal and related expenses decreased by 73.5% to $219,000 in fiscal
2000 from $826,000 in fiscal 1999. Expenses incurred in fiscal 2000 include the
defense of filed class action litigation and charges relating to the extension
of certain employee stock options. During fiscal 1999, expenses included
$325,000 of fees relating to our withdrawn public stock offering, $250,000 in
settlement of litigation with a former employee, expenses associated with our
reduction in force and legal expenses incurred to defend our company in a filed
class action litigation.
Interest and Other Income, Net. Interest income reflects income from the
investment of cash balances and marketable securities, net of expenses, relating
to those investments. Interest income rose 21.4% to $805,000 in fiscal 2000 from
$663,000 in fiscal 1999. This increase was the result of positive cash flows
invested in marketable securities, as well as higher yields on securities.
Income Taxes. We have significant net operating loss carryforwards ("NOLs")
and tax credit carryforwards. The $129,000 provision for income taxes in fiscal
2000 represented the estimated federal and state alternative minimum taxes
payable, reduced for the use of NOLs and tax credit carryforwards. Management
expects to use NOLs and other tax carryforward amounts to the extent income is
earned in fiscal 2001 and beyond. Therefore, our effective tax rate should
continue to be substantially less than the applicable statutory rates. As of
March 31, 2000, we had NOL carryforwards of $41.2 million available to reduce
future taxable income for federal income tax purposes and NOL carryforwards of
$867,000 available to reduce future taxable income for state income tax
purposes. Additionally, we had research and development and other tax credit
carryforwards available to reduce income taxes for federal income tax purposes
of $1.9 million and research and development and other tax credit carryforwards
available to reduce income taxes for state income tax purposes of $676,000. We
have historically experienced significant operating losses and operate in an
industry subject to rapid technological changes. Therefore, management believes
there is sufficient uncertainty regarding our ability to generate future taxable
income and use these NOLs and tax credit carryforwards such that a full
valuation allowance for deferred tax assets was required at March 31, 2000.
As a result of a change in our ownership which occurred in May 1990, there
is an annual limitation of approximately $1.5 million for federal and state
income tax purposes on the combined use of approximately $6.1 million of federal
NOLs and the use of $550,000 of federal and state tax credit carryforwards.
Additionally, as a result of our public offering in December 1992, NOLs and tax
credit carryforwards incurred before December 1992 are subject to an annual
limitation of $5.5 million for federal and state income tax purposes on the
combined use of $26.2 million of federal and $4.5 million of state NOLs, and the
use of $1.2 million of federal and $379,000 of state tax credit carryforwards.
If the amounts of these limitations are not used in a particular year, the
amount not used increases the limitation in the subsequent year.
LIQUIDITY AND CAPITAL RESOURCES
We have financed our operations primarily through the sale of equity
securities and, in fiscal 2000 and fiscal 1998, from net income from operations.
From inception to March 30, 2001, we raised $72.8 million in net proceeds from
equity financings. As of March 30, 2001, we had $12.4 million of cash, cash
equivalents and marketable securities. In addition to these amounts, we have
available an $8.0 million revolving bank line of credit agreement. While the
agreement is in effect, we are required to deposit assets with a collective
value, as defined in the line of credit agreement, equivalent to no less than
100% of the outstanding principal balance. Amounts outstanding under the line of
credit bear interest at the bank's prime rate. The line of credit agreement
expires on May 1, 2002. As of March 30, 2001, there were no borrowings
outstanding under the line of credit.
29
32
During fiscal 2001, we generated $2.3 million in cash from operating
activities compared to generated cash of $8.4 million in fiscal 2000. The cash
provided during fiscal 2001 was composed mainly of a net loss of $2.6 million
and non-cash items of $3.5 million in depreciation, impairment charges of $1.96
million, provision for doubtful accounts of $224,000 and inventory allowance of
$107,000, increased accrued payroll and benefits of $337,000 and a decrease in
prepaid and other accrued expenses of $188,000. This was partially offset by a
$1.4 million increase in accounts receivable. The cash generated from operations
in fiscal 2000 was primarily due to net income of $3.1 million, increases in
accounts payable and accrued liabilities of $1.9 million, increases in accrued
payroll and benefits of $573,000, reductions in accounts receivable and
inventory totaling $1.4 million and depreciation and amortization of $1.6
million, partially offset by increased prepaid expenses of $756,000.
In fiscal 2001, we used $5.8 million of cash in investing activities
through the purchase of property and equipment of $4.2 million, the final Health
Net purchase payment of $1.2 million and the net purchase of marketable
securities of $1.4 million, which was partially offset by the recovery of $1.0
million of restricted cash. In fiscal 2000, net cash used by investing
activities was $8.5 million, consisting primarily purchases of property and
equipment of $4.2 million, the purchase of Health Net for $2.3 million, the
creation of $1.0 million in restricted cash related to the final purchase price
adjustment for the Health Net acquisition and the net purchase of marketable
securities of $957,000.
Net cash provided by financing activities was $560,000 in fiscal 2001 as
compared to $1.4 million for fiscal 2000. For both years, cash provided by
financing activities was primarily from the issuance of common stock pursuant to
the employee stock purchase and employee stock incentive plans.
During fiscal 2002, we intend to expend approximately $4.2 million for
capital purchases related to expansion of our information technology systems,
expansion of our manufacturing capacity and research and development.
QUARTERLY FINANCIAL DATA
QUARTER ENDED
---------------------------------------------------------------------------------------
MAR. 30, DEC. 29, SEPT. 29, JUNE 30, MAR. 31, DEC. 24, SEPT. 24, JUNE 25,
2001 2000 2000 2000 2000 1999 1999 1999
-------- -------- --------- -------- -------- -------- --------- --------
Revenue:
Previously reported............. $10,238 $8,850 $8,488 $8,888 $8,564 $6,755 $6,328 $5,775
Reclassification................ -- -- 229 311 127 -- -- --
------- ------ ------ ------ ------ ------ ------ ------
Total revenue............ 10,238 8,850 8,717 9,199 8,691 6,755 6,328 5,775
Gross profit...................... 5,939 5,046 5,267 5,471 5,368 4,060 3,735 3,175
Net income (loss)................. $(3,033) $ (551) $ 29 $ 949 $1,477 $ 433 $ 730 $ 536
Earnings (loss) per share:
Basic........................... $ (0.25) $(0.05) $ 0.00 $ 0.08 $ 0.12 $ 0.04 $ 0.06 $ 0.05
Diluted......................... $ (0.25) $(0.05) $ 0.00 $ 0.08 $ 0.12 $ 0.04 $ 0.06 $ 0.05
Revenue and costs of revenue figures have been revised as a result of the
retroactive adoption of EITF 00-10 "Accounting for Shipping and Handling Fees
and Costs".
In the fourth quarter of fiscal 2001, we recorded an impairment charge of
$1.96 million in the WellCheck.com segment, for a write-off capitalized website
and database development cost.
In the fourth quarter of fiscal 2001, we recorded additional legal and
other charge of $1.3 million in regards to resolving a class action lawsuit.
RECENT ACCOUNTING PRONOUNCEMENTS
In June 1998, the Financial Accounting Standards Board issued SFAS No. 133
"Accounting for Derivative Instruments and Hedging Activities," which
establishes accounting and reporting standards for derivative instruments and
hedging activities. It requires that an entity recognize all derivatives as
either assets or liabilities on the balance sheet and measure those instruments
at fair value. The Company, to date, has not engaged in derivative and hedging
activities, and accordingly, does not believe that the adoption of SFAS
30
33
No. 133 will have a material impact on the financial reporting and related
disclosures of the Company. The Company will adopt SFAS No. 133, as required by
SFAS 137, "Accounting for Derivative Instruments and Hedging
Activities -- Deferral of the Effective Date of the FASB Statement No. 133,"
beginning with the first quarter of fiscal 2002.
In the first quarter of 2001, the Financial Accounting Standards Board
issued an Exposure Draft related to business combinations. If the final results
are adopted as proposed, as of January 1, 2002, the Company will no longer be
required to amortize goodwill as a charge to earnings. In addition, the Company
will be required to periodically review goodwill for potential impairment. If an
impairment is found to exist, a charge will be taken against earnings in the
Company's consolidated statement of operations. The Company cannot currently
determine the amount of an impairment charge, if any, that would be recorded
upon adoption.
FACTORS AFFECTING FUTURE OPERATING RESULTS
WE HAVE NO PRIOR EXPERIENCE IN THE TESTING SERVICES BUSINESS, AND IF THIS NEW
BUSINESS IS NOT SUCCESSFUL, WE WILL BE GREATLY HARMED.
The testing services business being pursued by our WellCheck business unit
is completely new to us and our management team. This will make it more
difficult for us to successfully develop this new business. Also, we will be
devoting significant resources to developing this new business. If we are not
successful in developing this new business, our Diagnostic Products business
will be greatly harmed. Even if we are successful at developing the new
business, the demands of attempting to grow this new business may prevent us
from devoting significant time and attention to our traditional Diagnostic
Products business, and that business may decline.
OUR OPERATING RESULTS MAY SUFFER IF WE ARE UNABLE TO MANAGE GEOGRAPHICALLY
DIVERSE OPERATIONS.
We have managed and operated our traditional business almost exclusively
from our Hayward, California headquarters. Our new WellCheck business requires
us to operate in multiple geographically dispersed locations and adapt our
management and financial systems and controls to this new geographically
dispersed business. If we cannot successfully manage our geographic expansion,
the testing services business will not succeed and we will not recover our large
investment in the testing services business. As a result, our business would
suffer.
OUR NEW TESTING SERVICES BUSINESS REQUIRES SIGNIFICANT MANAGEMENT ATTENTION AND
FINANCIAL RESOURCES TO DEVELOP AND IF THIS NEW BUSINESS IS NOT SUCCESSFUL, OUR
BUSINESS WILL SUFFER.
The continued development of our new testing services business will require
significant management attention and financial resources. These expenditures are
likely to materially affect our operating results as a whole. We may need to
seek additional capital to help fund these start-up expenses. The required
additional capital may not be available to us at favorable or acceptable terms
when required, or at all. If we cannot obtain required additional capital, we
may have to change our business strategy, which would be disruptive to our
business. If we raise additional capital through borrowings, the terms of such
borrowings may impose limitations on how our management may operate the business
in the future. If we raise additional capital by issuing equity, this may result
in a dilution of existing shareholders' interests in us. Also, equity issued by
us may have rights, preferences or privileges senior to those of our existing
shareholders.
IF WE FAIL TO INTEGRATE ANY FUTURE ACQUISITIONS, OUR BUSINESS WILL BE HARMED.
We may use acquisitions of existing testing services businesses as a
significant part of the development of our new testing business. These
acquisitions could be very costly, could result in dilution to existing
investors and could result in integration problems that harm the business as a
whole. Any acquisition could result in expending significant amounts of cash,
issuing potentially dilutive equity securities or incurring debt or amortization
expenses related to goodwill and other intangible assets. Any of these
acquisition financing approaches could materially harm our operating results and
business. Acquisitions may also result in difficulties in assimilating the
operations, technologies, products, services and personnel of the acquired
31
34
company or business. These difficulties could result in additional expenses and
in diversion of management attention, which could prevent the new business from
being successful. Any of these results could harm us financially.
OUR L-D-X SYSTEM HAS NOT YET ACHIEVED BROAD MARKET ACCEPTANCE IN ALL OF OUR
TARGET MARKETS AND IF BROAD MARKET ACCEPTANCE DOES NOT OCCUR, OUR OPERATING
RESULTS WILL BE HARMED.
Our L-D-X System, including the L-D-X Analyzer (our only product platform)
and single-use test cassettes, will continue to account for substantially all of
the revenue of our Diagnostics Products business for the foreseeable future. If
this revenue does not grow, our overall business will be severely harmed. For us
to increase revenue, sustain profitability and maintain positive cash flows from
operations, the L-D-X System must gain much broader market acceptance among
health care providers, particularly physician office laboratories and
pharmacies. We have made only limited sales to physician office laboratories and
pharmacists to date relative to the size of the available markets. Factors that
could prevent broad market acceptance of the L-D-X System include:
- Low levels of awareness of the availability of our technology in both the
physician and other customer groups;
- The L-D-X System's accuracy, ease of use, rapid test time, reliability
and cost effectiveness compared to other testing alternatives;
- The growing prevalence of managed care may adversely affect the physician
office laboratory market, as a growing number of physicians are salaried
employees and have no financial incentive to perform testing;
- Many managed care organizations have contracts with laboratories, which
require participating or employed physicians to send patient specimens to
contracted laboratories;
- Physicians are under growing pressure by Medicare and other third party
payors to limit their testing to "medically necessary" tests; and
- Limited availability and amount of reimbursement for performing tests on
the L-D-X System.
If we do not achieve broad market acceptance, our Diagnostic Products
business will not grow. Even if we are successful in continuing to place L-D-X
Analyzers at physician office laboratories, pharmacies and other near-patient
testing sites, there can be no assurance that placement of L-D-X Analyzers will
result in sustained demand for our single-use test cassettes. We are relying in
significant part on income from the core Diagnostic Product business to finance
our strategic expansion. If the Diagnostic Products business does not grow, the
new business will not succeed. These results will cause severe financial harm to
us.
As a result of these many hurdles to achieving broad market acceptance for
the L-D-X System, demand for the L-D-X System may not be sufficient to sustain
revenue and profits from operations. Because the L-D-X System currently
contributes the vast majority of our revenue, we could be required to cease
operations if the L-D-X System does not achieve and maintain a significant level
of market acceptance.
OUR BUSINESS HAS EXPERIENCED A HISTORY OF OPERATING LOSSES AND FLUCTUATING
OPERATING RESULTS, WHICH MAY CAUSE OUR STOCK PRICE TO FALL.
Historically, we have experienced significant operating losses and negative
cash flows from operations. As of March 30, 2001, we had an accumulated deficit
of $48.0 million. Our first profitable quarter was the second quarter of fiscal
1998, and our first profitable year was fiscal 1998. However, we recorded a net
loss of $2.6 million for fiscal 2001. Our profitability and positive cash flows
from operations in the future will require:
- Broadening market acceptance of our existing product offerings;
- Successfully developing, introducing and marketing additional test
cassettes or other products for our Diagnostic Products business; and
- Successfully developing our new testing services business.
32
35
WE MAY EXPERIENCE SIGNIFICANT FLUCTUATIONS IN REVENUE AND RESULTS OF OPERATIONS
ON A QUARTER TO QUARTER BASIS IN THE FUTURE. QUARTERLY OPERATING RESULTS WILL
FLUCTUATE DUE TO NUMEROUS FACTORS, INCLUDING:
- The timing and amount of expenditures required for the continued
development of our new testing services business;
- The timing and level of market acceptance of the L-D-X System;
- The timing of the introduction and availability of new tests;
- The timing and level of expenditures associated with research and
development activities;
- The timing and level of expenditures associated with expansion of sales
and marketing activities and overall operations;
- Our ability to reduce the cost of cassette manufacturing;
- Variations in manufacturing efficiencies;
- The timing and establishment of strategic distribution arrangements and
the success of the activities conducted under such arrangements;
- Changes in demand for our products based on changes in third party
reimbursement, competition, changes in government regulation and other
factors;
- The timing of significant orders from, and shipments, to customers;
- Product pricing and discounts;
- Variations in the mix of products sold; and
- General economic conditions.
These and other factors are difficult to predict and could have a material
adverse effect on our business, financial condition and results of operations.
Fluctuations in quarterly demand for our products may cause our manufacturing
operations to fluctuate in volume, increase uncertainty in operational planning
and/or affect cash flows from operations. Many of our expenses are made in
advance, based on our expectations of future business needs. These costs are
largely fixed in the short term. As a result, when business levels do not meet
expectations, our fixed costs will not be recovered and we will experience
losses. This situation is likely to result in the future because of the
variability and unpredictability of our revenue. This also means that our
results will likely not meet the expectations of public market security analysts
or investors at one time or another, which could cause the trading price of our
common stock to decline significantly.
IF WE DO NOT SUCCESSFULLY DEVELOP, INTRODUCE AND MARKET NEW TESTS, OUR BUSINESS
WILL BE HARMED.
Most of our revenue comes from our Diagnostics Products business. We
anticipate this will continue for the near term. We also rely on revenue from
the Diagnostics Products business to fund the development of our new testing
services business. We believe our Diagnostic Products business will not grow
significantly if we do not develop new tests to use with the L-D-X System. If
new tests are not developed and accepted in the market, our business will not
grow significantly and will be harmed. Developing new tests involves many
significant problems and risks, including:
- Research and development is a very expensive process;
- Research and development takes a very long time to result in a marketable
product;
- Significant costs (including diversion of resources) may be incurred in
development before knowing if the development will result in a test that
is commercially viable;
- A new test will not be successful unless it is effectively marketed to
its target market;
- The manufacturing process for a new test must be reliable,
cost-efficient, and high-volume and must be developed and implemented in
a timely manner to produce the test for sale;
33
36
- New tests must meet a significant market need to be successful; and
- New tests must obtain proper regulatory approvals to be marketed.
We could experience difficulties that delay or prevent the successful
development, introduction and marketing of new tests. For example, regulatory
clearance or approval of any new tests may not be granted on a timely basis, or
at all. We have experienced difficulties obtaining regulatory approval for tests
in the past. Because the FDA's evaluation of applications for CLIA waived status
is not based on precisely defined, objectively measurable criteria, we cannot
predict the likelihood of obtaining waived status for future products.
WE FACE RISKS FROM FAILURES IN OUR MANUFACTURING PROCESSES.
We internally manufacture all of the single-use test cassettes that are
used with the L-D-X Analyzer. The manufacture of single-use test cassettes is a
highly complex and precise process that is sensitive to a wide variety of
factors. We have, in the past, experienced lower than expected manufacturing
yields that have adversely affected gross margins and delayed product shipments.
If we do not maintain acceptable manufacturing yields of test cassettes or
experience product shipment delays, our business, financial condition and
results of operations could be materially adversely affected. We may reject or
be unable to sell a substantial percentage of test cassettes because of:
- Raw materials variations or impurities;
- Manufacturing process variances and impurities; and
- Decreased manufacturing equipment performance.
Our cassette manufacturing lines would be costly and time consuming to
repair or replace if their operation were interrupted. The interruption of our
manufacturing operations or the loss of employees dedicated to the manufacturing
facility could severely harm our business. The risks involving our manufacturing
lines include:
- As our production levels have increased, we have been required to use our
machinery more hours per day and the down time resulting from equipment
failure has increased;
- The custom nature of much of our manufacturing equipment increases the
time required to remedy equipment failures and replace equipment;
- We have a limited number of employees dedicated to the operation and
maintenance of our manufacturing equipment, the loss of whom could impact
our ability to effectively operate and service such equipment; and
- We manufacture all cassettes at our Hayward, California manufacturing
facility, so manufacturing operations are at risk to interruption from
earthquake, fire, power outages or other events affecting this one
location.
WE RELY ON A CONTINUOUS POWER SUPPLY TO CONDUCT OUR OPERATIONS, AND CALIFORNIA'S
CURRENT ENERGY CRISIS COULD DISRUPT OUR OPERATIONS AND INCREASE OUR EXPENSES.
California is in the midst of an energy crisis that could disrupt our
operations and increase our expenses. In the event of an acute power shortage
(i.e. when power reserves for the State of California fall below 1.5%),
California has on some occasions implemented, and may in the future continue to
implement, rolling blackouts throughout California. We currently have backup
generators to maintain only a limited amount of power and no alternate sources
of power in the event of a prolonged blackout. Our current insurance does not
provide coverage for any damages we or our customers may suffer as a result of
any interruption in our power supply. If blackouts interrupt our power supply,
we would be temporarily unable to continue operations at our facilities. Any
such interruption in our ability to continue operations at our facilities could
damage our reputation, harm our ability to retain existing customers and to
obtain new customers and could result in lost revenue, any of which could
substantially harm our business and results of operations.
34
37
OUR OPERATING RESULTS MAY SUFFER IF WE DO NOT REDUCE OUR MANUFACTURING COSTS.
We believe we will be required to reduce manufacturing costs for new and
existing test cassettes to achieve sustained profitability. We currently operate
two manufacturing lines for dry chemistry cassettes. We are installing and
validating a third manufacturing line that is currently in preproduction
validation and should be fully operational in July 2001. The complexity and
custom nature of our manufacturing process increases the amount of time and
money required to add an additional manufacturing line. Despite our efforts, the
new manufacturing line may not be completed in a timely fashion, or at all.
Also, we may need to implement additional cassette manufacturing cost reduction
programs. Failure to implement the new dry chemistry manufacturing line could
prevent us from satisfying customer orders in a timely manner, which could lead
to customer dissatisfaction and loss of business. Failure to implement the new
line could also prevent us from reducing manufacturing costs for dry chemistry
tests, and prevent us from achieving sustained profitability.
OUR OPERATING RESULTS MAY SUFFER IF WE DO NOT DEVELOP NEW MANUFACTURING
PROCESSES AND A NEW MANUFACTURING LINE TO MARKET IMMUNOASSAY TESTS IN
DEVELOPMENT.
We may be required to build a new cassette manufacturing line to
manufacture the immunoassay test cassettes under development. To date, we have
not developed the processes and production equipment necessary for an
immunoassay cassette manufacturing line. If we fail to successfully develop an
immunoassay cassette manufacturing line and achieve acceptable yields we may not
be able to cost-effectively satisfy customer orders. This development would have
a material adverse effect on our business, financial condition and results of
operations.
WE DEPEND ON SINGLE SOURCE SUPPLIERS FOR INPUTS TO OUR MANUFACTURING PROCESS AND
FAILURE OF OUR SUPPLIERS TO PROVIDE SUPPLIES TO US COULD HARM OUR BUSINESS.
We currently depend on single source vendors to provide subassemblies,
components and raw materials used in the manufacture of our products. Any supply
interruption in a single source subassembly, component or raw material could
restrict our ability to manufacture products until a new source of supply is
identified and qualified. We may not be successful in qualifying additional
sources of supply on a timely basis, or at all. Failure to obtain a usable
alternative source could prevent us from manufacturing our products, resulting
in inability to fill orders, customer dissatisfaction and loss of business. This
would likely severely harm our business. In addition, an uncorrected impurity or
supplier's variation in a raw material, either unknown to us or incompatible
with our manufacturing process, could interfere with our ability to manufacture
products. Because we are a small customer of many of our suppliers and we
purchase their subassemblies, components and materials with purchase orders
instead of long term commitments, our suppliers may not devote adequate
resources to supplying our needs. Any interruption or reduction in the future
supply of any subassemblies, components or raw materials currently obtained from
single or limited sources could severely harm our business.
IF WE ARE SUCCESSFUL IN GROWING SALES, OUR BUSINESS WILL BE HARMED IF WE CANNOT
EFFECTIVELY MANAGE THE OPERATIONAL AND MANAGEMENT CHALLENGES OF GROWTH.
If we are successful in achieving and maintaining market acceptance for the
L-D-X System, we will be required to expand our operations, particularly in the
areas of sales, marketing and manufacturing. As we expand our operations, this
expansion will likely result in new and increased responsibilities for
management personnel and place significant strain on our management, operating
and financial systems and resources. To accommodate any such growth and compete
effectively, we will be required to implement and improve our information
systems, procedures and controls, and to expand, train, motivate and manage our
work force. Our personnel, systems, procedures and controls may not be adequate
to support our future operations. Any failure to implement and improve
operational, financial and management systems or to manage our work force as
required by future growth, if any, could harm our business and prevent us from
improving our financial condition as a result of increased sales.
35
38
WE DEPEND ON DISTRIBUTORS TO SELL OUR PRODUCTS, AND HAVE HAD DIFFICULTY IN THE
PAST MAINTAINING SOME DISTRIBUTOR RELATIONSHIPS.
To increase revenue and achieve sustained profitability, we will have to
maintain and expand our existing distribution relationships and develop new
distribution relationships. We are dependent on such distributors to assist us
in promoting market acceptance of the L-D-X System. If we do not maintain and
expand these relationships, our sales will not grow and our business will be
greatly harmed. We have in the past had problems maintaining relationships with
our distributors to the pharmacy market. Distribution agreements with
AmeriSource Health Corporation and Bergen Brunswig Corporation, both national
distributors to the pharmacy market, were cancelled due to contractual
performance issues. Also, we may not be able to enter into and maintain new
arrangements on a timely basis, or at all. Even if we do enter into additional
distributor relationships, those distributors may not devote the resources
necessary to provide effective sales and marketing support to our products. We
do not have the ability to prevent distributors from distributing products that
compete with our products. The distributors may also give higher priority to the
products of our competitors.
WE RELY ON A LIMITED NUMBER OF CUSTOMERS FOR A SUBSTANTIAL PART OF OUR REVENUE.
Sales to a limited number of customers have accounted for a significant
portion of our revenue in each fiscal period. We have experienced periods in
which sales to some of our major customers, as a percentage of total revenue,
have fluctuated due to delays or failures to place expected orders. We expect
that sales to a limited number of customers will continue to account for a
substantial portion of our total revenue in future periods. In fiscal 2000,
Physician Sales and Service, Inc. accounted for approximately 16.9 % of our
total revenue and GMR accounted for less than 1% of our total revenue. In fiscal
2001, Physician Sales and Service, Inc. accounted for approximately 16.4% of our
total revenue and GMR accounted for approximately 7.4% of our total revenue. We
do not have long-term agreements with any of our customers. Customers generally
purchase our products pursuant to cancelable short-term purchase orders. Our
results of operations have been negatively affected in the past by the failure
of anticipated orders to materialize and by delays in or cancellations of
orders. If we were to lose a major customer or if orders by or shipments to a
major customer were to otherwise decrease or be delayed, our results of
operations would be harmed.
IF THIRD PARTY REIMBURSEMENT FOR USE OF OUR PRODUCTS IS ELIMINATED OR REDUCED,
OUR SALES WILL BE GREATLY REDUCED AND OUR BUSINESS MAY FAIL.
In the United States, healthcare providers that purchase products such as
the L-D-X System generally rely on third party payors, including private health
insurance plans, federal Medicare, state Medicaid and managed care
organizations, to reimburse all or part of the cost of the procedure in which
the product is being used. We will not be able to successfully market our
products if their purchase and use is not subject to reimbursement from
government health authorities, private health insurers and other third party
payors. If this reimbursement is not available or is limited, healthcare
providers will be much less likely to use our products, our sales will be
greatly reduced and our business will likely fail.
There are current conditions in the healthcare industry that increase the
possibility that third party payors may reduce or eliminate reimbursement for
tests using our products in certain settings. These conditions include:
- Third party payors increasingly scrutinize and challenge the prices
charged for medical products and services;
- Healthcare providers are moving toward a managed care system in which
they provide comprehensive healthcare for a fixed cost per patient and
authorize fewer elective procedures, such as uses of our products for
diagnostic screening;
- General uncertainty regarding what changes will be made in the
reimbursement methods used by third party payors and how that will affect
use of products such as ours, which may deter healthcare providers from
adopting the use of our products; and
36
39
- An overall escalating cost of medical products and services has led to
and will continue to lead to increased pressures on the healthcare
industry, both domestic and international, to reduce the cost of products
and services, including products offered by us.
Market acceptance of our products in international markets is also
dependent, in part, on the availability of reimbursement within prevailing
healthcare systems. Reimbursement and healthcare systems in international
markets vary significantly by country and include both government sponsored
healthcare and private insurance. Third party reimbursement and coverage may not
be available or adequate in either the United States or international markets,
and current reimbursement amounts may be decreased in the future. Also, future
legislation, regulation or reimbursement policies of third party payors may
adversely affect demand for our products or our ability to sell our products on
a profitable basis. Any of these events could materially harm our business. See
"Business -- Third Party Reimbursement."
IF THE HEALTHCARE SYSTEM IN THE UNITED STATES UNDERGOES FUNDAMENTAL CHANGE,
THESE CHANGES MAY HARM OUR BUSINESS.
We believe the healthcare industry in the United States is likely to
undergo fundamental changes due to current political, economic and regulatory
influences. We anticipate that Congress, state legislatures and the private
sector will continue to review and assess alternative healthcare delivery and
payment systems. Potential alternatives include mandated basic healthcare
benefits, controls on healthcare spending through limitations on the growth of
private health insurance premiums and Medicare and Medicaid spending, the
creation of large insurance purchasing groups, price controls and other
fundamental changes to the healthcare delivery system. We expect legislative
debate to continue in the future and for market forces to demand reduced costs.
We cannot predict what impact the adoption of any federal or state health care
reform measures, future private sector reform or market forces may have on our
business. Any changes in the healthcare system could potentially have extremely
negative effects on our business.
OUR PRODUCTS ARE SUBJECT TO MULTIPLE LEVELS OF GOVERNMENT REGULATION AND ANY
REGULATORY CHANGES ARE DIFFICULT TO PREDICT AND COULD BE DAMAGING TO OUR
BUSINESS.
The manufacture and sale of our diagnostic products, including the L-D-X
System, are subject to extensive regulation by numerous governmental
authorities, principally the Food and Drug Administration and corresponding
state and foreign regulatory agencies. We are not able to commence marketing or
commercial sales in the United States of any of the new tests we develop until
we receive required clearances and approvals. The process of obtaining required
regulatory clearances and approvals is lengthy, expensive and uncertain. As a
result, our new tests under development, even if successfully developed, may
never obtain such clearance or approval. Additionally, certain material changes
to products that have already been cleared or approved are subject to further
review and clearance or approval. Medical devices are subject to continual
review, and later discovery of previously unknown problems with a cleared
product may result in restrictions on the product's marketing or withdrawal of
the product from the market. If we lose previously obtained clearances, or fail
to comply with existing or future regulatory requirements, we may not be able to
market the affected products, which would depress our revenue and severely harm
our business.
In addition, any future amendment of or addition to regulations impacting
our products could prevent us from marketing the L-D-X System. Regulatory
changes could hurt our business by increasing burdens on our products or by
reducing or eliminating certain competitive advantages of the L-D-X System's
waived status.
Food and Drug Administration clearance or approval of products such as ours
can be obtained by either of two processes:
- The 510(k) clearance process, which generally takes from four to twelve
months but may take longer; and
- The pre-market approval process, which is a longer and more costly
process than a 510(k) clearance process, involves the submission of
extensive supporting data and clinical information and generally takes
one to three years but may take significantly longer.
37
40
If our future products are required to obtain a pre-market approval, this
would significantly delay our ability to market those tests and significantly
increase the costs of development.
The use of our products and those of our competitors is also affected by
federal and state regulations, which provide for regulation of laboratory
testing, as well as by the laws and regulations of foreign countries. The scope
of these regulations includes quality control, proficiency testing, personnel
standards and inspections. In the United States, clinical laboratory testing is
regulated under the Clinical Laboratory Improvement Act of 1976. The L-D-X
Analyzer, our total cholesterol, high density lipoproteins, triglycerides and
glucose tests in any combination and our ALT test cassette have been classified
as waived from the application of many of the requirements under the Clinical
Laboratory Improvement Act. We believe this waived classification is critical
for our products to be successful in their markets. Any failure of our new tests
to obtain waived status under the Clinical Laboratory Improvement Act will
severely limit our ability to commercialize such tests. Loss of waived status
for existing diagnostic products or failure to obtain waived status for new
products could limit our sales and revenue, which would severely harm our
business.
WE MAY FACE FINES OR OUR MANUFACTURING FACILITIES COULD BE CLOSED IF WE FAIL TO
COMPLY WITH MANUFACTURING AND ENVIRONMENTAL REGULATIONS.
Our manufacturing processes and, in certain instances, those of our
contract manufacturers, are subject to stringent federal, state and local
regulations governing the use, generation, manufacture, storage, handling and
disposal of certain materials and wastes. Failure to comply with present or
future regulations could result in many things, including warning letters,
fines, injunctions, civil penalties, recall or seizure of products, total or
partial suspension of production, refusal of the government to grant pre-market
clearance or pre-market approval for devices, withdrawal of approvals and
criminal prosecution. Any of these could harm our business. We and our contract
manufacturers are also subject to federal, state and foreign regulations
regarding the manufacture of healthcare products and diagnostic devices,
including:
- Quality system regulations, which requires the maintenance of a quality
system consistent with FDA regulations;
- ISO9001/EN46001 requirements, which is an industry standard for
maintaining and assuring conformance to quality standards; and
- Other foreign regulations and state and local health, safety and
environmental regulations, which include testing, control and
documentation requirements.
Changes in existing regulations or adoption of new governmental regulations
or policies could prevent or delay regulatory approval of our products or
require us to incur significant costs to comply with manufacturing and
environmental regulations, which could harm our business.
OUR BUSINESS DEPENDS ON OUR ABILITY TO PROTECT OUR PROPRIETARY TECHNOLOGY
THROUGH PATENTS AND OTHER MEANS, WHICH MAY NOT BE SUCCESSFUL OR MAY REQUIRE
COSTLY LITIGATION TO ENFORCE.
Our success will depend in part on our ability to develop and maintain the
proprietary aspects of our technology and operate without infringing the
proprietary rights of others. We have nine United States patents and have filed
patent applications relating to our technology internationally under the Patent
Cooperation Treaty and individual foreign patent applications. The risks of
relying on the proprietary nature of our technology include:
- Our pending patent applications may not result in the issuance of any
patents, or, if issued, such patents may not offer protection against
competitors with similar technology;
- Our patents may be challenged, invalidated or circumvented in the future,
and the rights created under our patents may not provide a competitive
advantage;
- Competitors, many of which have substantially greater resources than us
and have made substantial investments in competing technologies, may seek
to apply for and obtain patents covering technologies that are more
effective than ours. This could render our technologies or products
obsolete or
38
41
uncompetitive or could prevent, limit or interfere with our ability to
make, use or sell our products either in the United States or in
international markets;
- The medical products industry has been characterized by extensive
litigation regarding patents and other intellectual property rights; and
- An adverse determination in litigation or interference proceedings to
which we may become a party could subject us to significant liabilities
to third parties or require us to seek licenses from third parties, which
may not be available on commercially reasonable terms or at all.
We may in the future become subject to patent infringement claims and
litigation or interference proceedings conducted in the United States Patent and
Trademark Office to determine the priority of inventions. Litigation may also be
necessary to enforce any patents issued to us, to protect our trade secrets or
know-how or to determine the enforceability, scope and validity of the
proprietary rights of others. The defense and prosecution of intellectual
property suits, patent interference proceedings and related legal and
administrative proceedings are both costly and time consuming and will likely
result in substantial diversion of attention of technical and management
personnel.
In the past, patent infringement claims have been asserted against us. In
December 1999, an injunction was filed in Zug, Switzerland by Roche Diagnostics,
a subsidiary of Roche Holdings, Ltd., seeking a cease and desist order barring
us and two of our distributors from distributing HDL assay single-use test
cassettes in Switzerland. The complaint alleges that we violated a Roche
European patent for HDL. The court is expected to reach a decision on the merits
of the complaint in the next several months. Additionally, in January 2000, a
complaint was filed in the District Court, Dusseldorf, Germany against us and
two of our distributors seeking a cease and desist order barring the
distributors from shipping HDL single-use test cassettes into Germany. The
complaint alleges we and our distributors violated a Roche German priority
patent for HDL by selling our single-use test cassette containing a HDL assay.
The court has requested additional information be submitted by both parties, but
has not made any ruling or set additional court dates. In September 2000, we
were served a complaint, No. Ei/Ti ROCH 04002, filed in Vienna, Austria by Roche
Diagnostics, seeking a cease and desist order barring us and one of our
distributors from distributing HDL assay single-use test cassettes in Austria.
The complaint alleges that we violated a Roche European patent for HDL. At this
point, no schedule has been set regarding court activity. We believe all suits
are without merit and intend to defend the cases vigorously. We do not believe
that we engaged in any wrongdoing and that the outcome of this matter will not
result in a material adverse effect; however, there can be no assurance that the
lawsuits will be resolved in our favor.
We rely on trade secrets, technical know-how and continuing invention to
develop and maintain our competitive position. Others may independently develop
substantially equivalent proprietary information and techniques or otherwise
gain access to our trade secrets or disclose such technology. We may also not be
able to meaningfully protect our right to our trade secrets.
WE DEPEND ON TECHNOLOGY THAT WE LICENSE FROM OTHERS, WHICH MAY NOT BE AVAILABLE
TO US IN THE FUTURE AND WOULD PREVENT US FROM PRODUCING OUR PRODUCTS AND
SEVERELY HARM OUR BUSINESS.
Our current products incorporate technologies which are the subject of
patents issued to, and patent applications filed by, others. We have obtained
licenses for certain of these technologies. We may in the future be required to
obtain licenses for new products. We may not be able to obtain licenses for
technology patented by others on commercially reasonable terms, or at all. We
also may not be able to develop alternative approaches if we are unable to
obtain licenses. Also, our current and future licenses may not be adequate for
the operation of our business. Failure to obtain adequate licenses on
commercially reasonable terms could prevent us from producing our products and
severely harm our business.
39
42
WE MAY NOT BE ABLE TO EFFECTIVELY COMPETE AGAINST OTHER PROVIDERS OF DIAGNOSTIC
PRODUCTS AND TESTING SERVICES, WHICH COULD CAUSE OUR SALES TO DECLINE.
The markets for diagnostic products and testing services in which we
operate are intensely competitive. Our competition consists mainly of clinical
and hospital laboratories, as well as manufacturers of bench top analyzers. To
achieve market acceptance for the L-D-X System, we must demonstrate that the
L-D-X System is an attractive alternative to bench top analyzers as well as to
clinical and hospital laboratories. This will require physicians to change their
established means of having such tests performed. The L-D-X System may not be
able to compete with these other testing services and analyzers. In addition,
companies having a significant presence in the market for therapeutic
monitoring, such as Abbott Laboratories, Beckman Coulter, Inc. and Roche
Diagnostics, (a subsidiary of Roche Holding, Ltd.) have developed or are
developing analyzers designed for near-patient testing. These competitors have
substantially greater financial, technical, research and other resources and
larger, more established marketing, sales, distribution and service
organizations than us. These competitors also offer broader product lines than
us, have greater name recognition than us and offer discounts as a competitive
tactic. In addition, several smaller companies are currently making or
developing products that compete or will compete with ours. We may not have the
financial resources, technical expertise or marketing, distribution or support
capabilities to compete successfully in the future. Even if we do have such
resources and capabilities, we may not employ them successfully.
FAILURE TO RETAIN OUR KEY PERSONNEL AND ATTRACT ADDITIONAL QUALIFIED EMPLOYEES
COULD HURT OUR OPERATIONS.
Our success depends in significant part on the continued service of certain
key scientific, technical, regulatory and managerial personnel. Our success will
also require us to continue to attract and retain additional highly qualified
personnel in those areas. Competition for qualified personnel is intense,
particularly in the San Francisco Bay Area where we are located, because of the
number of attractive technology employment opportunities and the extremely high
cost of living. We may not be able to retain our key personnel or attract or
retain other necessary highly qualified personnel in the future. If we do not
keep our key personnel or attract other needed employees, we will not be able to
grow our business.
SALE OF OUR DIAGNOSTIC PRODUCTS AND PERFORMANCE OF OUR SERVICES MAY SUBJECT US
TO LIABILITY CLAIMS, AND IF OUR INSURANCE IS INSUFFICIENT, THIS LIABILITY COULD
SEVERELY HARM OUR BUSINESS.
Sale of our products and performance of our testing services entail risk of
product and professional claims. If any of these claims are brought, we may have
to expend significant resources defending against them. If we are found liable
for any of these claims, we may have to pay damages that could severely hurt our
financial position. Loss of these claims could also hurt our reputation,
resulting in our losing business and market share. The medical testing industry
has historically been litigious, and we face financial exposure to these
liability claims if use of our products results in personal injury or improper
diagnosis. We also face the possibility that defects in the design or
manufacture of our products might necessitate a product recall.
We currently maintain product liability professional liability insurance,
but there can be no assurance that the coverage limits of our insurance policies
will be adequate. Insurance is expensive and difficult to obtain, and product
liability insurance may not be able to be maintained in the future on acceptable
terms, in sufficient amounts to protect us against losses due to product
liability. Inability to maintain insurance at an acceptable cost or to otherwise
protect against potential product liability could prevent or inhibit the
continued commercialization of our products. In addition, a product liability
claim in excess of relevant insurance coverage or a product recall could
severely hurt our financial condition.
WE MAY NEED ADDITIONAL CAPITAL IN THE FUTURE TO SUPPORT OUR GROWTH, AND SUCH
ADDITIONAL FUNDS MAY NOT BE AVAILABLE TO US.
We intend to expend substantial funds for capital expenditures related to
expansion of our manufacturing capacity, research and development, expansion of
sales and marketing activities and other working capital and general corporate
purposes. Also, we plan to expend significant amounts in developing our new
testing services business. Although we believe our cash, cash equivalents,
marketable securities, cash flow anticipated to be
40
43
generated by future operations and available bank borrowings under an existing
line of credit will be sufficient to meet our operating requirements for the
foreseeable future, we may still require additional financing. For example, we
may be required to expend greater than anticipated funds if unforeseen
difficulties arise in expanding manufacturing capacity for existing cassettes or
in the course of completing required additional development, obtaining necessary
regulatory approvals, obtaining waived status under CLIA or introducing or
scaling up manufacturing for new tests. Developing our new testing services
business may also require more capital than we currently anticipate. This
possibility is increased given our lack of experience in the markets addressed
by this new business.
If additional financing is needed, we may seek to raise additional funds
through public or private financing, collaborative relationships or other
arrangements. Any additional equity financing may be dilutive to shareholders
and debt financing, if available, may involve restrictive covenants.
Collaborative arrangements, if necessary to raise additional funds, may require
us to relinquish our rights to technologies, products or marketing territories.
Our failure to raise capital on acceptable terms when needed could prevent us
from developing our products and our business.
WE HAVE MADE USE OF DEVICES TO LIMIT THE POSSIBILITY THAT WE ARE ACQUIRED, WHICH
MAY MEAN THAT A TRANSACTION THAT SHAREHOLDERS ARE IN FAVOR OF OR ARE BENEFITED
BY MAY BE PREVENTED.
Our board of directors has the authority to issue up to 5,000,000 shares of
preferred stock and to determine the rights, preferences, privileges and
restrictions of such shares without any further vote or action by our
shareholders. To date, our board of directors has designated 25,000 shares as
Series A participating preferred stock in connection with our "poison pill"
anti-takeover plan. The issuance of preferred stock under certain circumstances
could have the effect of delaying or preventing an acquisition of our company or
otherwise adversely affecting the rights of the holders of our stock. The
"poison pill" may have the effect of rendering more difficult or discouraging an
acquisition of our company which is deemed undesirable by our board of
directors. The "poison pill" may cause substantial dilution to a person or group
attempting to acquire us on terms or in a manner not approved by our board of
directors, except pursuant to an offer conditioned on the negation, purchase or
redemption of the rights issued under the "poison pill."
OUR STOCK PRICE IS LIKELY TO CONTINUE TO BE VOLATILE, WHICH COULD RESULT IN
SUBSTANTIAL LOSSES FOR INVESTORS.
The market price of our stock has in the past been, and is likely in the
future to continue to be, highly volatile. These fluctuations could result in
substantial losses for investors. Factors that cause our stock price to
fluctuate include:
- Quarterly variations in our operating results;
- Announcements by us and our competitors of technological innovations or
new commercial products;
- Government regulation;
- Changes in the current structure of the healthcare financing and payment
systems;
- Developments in or disputes regarding patent or other proprietary rights;
- Stock market price and volume fluctuations, which have particularly
affected the market prices for medical products and high technology
companies and which are often been unrelated to the operating performance
of such companies; and
- General economic, political and market conditions.
In the past, following periods of volatility in the market price of a
company's stock, securities class action suits have been filed against the
issuing company. This type of litigation has been brought against us in the past
and could be brought against us in the future, which would result in substantial
costs and a diversion of management's attention and resources. Any adverse
determination in such litigation could also subject us to significant
liabilities.
41
44
IF THIRD PARTY SPONSORSHIP OF OUR TESTING SERVICES BUSINESS IS ELIMINATED OR
REDUCED, OUR REVENUE WILL BE GREATLY REDUCED AND OUR BUSINESS MAY FAIL.
WellCheck derives the majority of its revenue from third parties using our
testing services to promote their products. If the third parties decline to
participate in the future or the amount of sponsorship is reduced, consumers
will be much less likely to use our testing services and our revenue will be
greatly reduced and our business will likely fail. Our WellCheck segment has a
contract with GMR which is in effect until January 2002, but can be cancelled
with a thirty day notice.
WE MUST LOCATE AN ADEQUATE NUMBER OF TESTING VENUES FOR THE TESTING SERVICES
BUSINESS.
For our testing services business to succeed, we must maintain the current
number of testing sites and find a greater number of locations and more diverse
venues to perform consumer testing. We must convince operators of the venues of
the testing services' economic benefits. If the number of testing sites do not
increase or are reduced, our business could be harmed.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
QUANTITATIVE DISCLOSURES
Our exposure to market risks is inherent in our operations, primarily to
interest rates relating to our investment portfolio. We do not use derivative
financial instruments in our investment portfolio and had no holdings of
derivative financial or commodity instruments at March 30, 2001.
We are subject to interest rate risks on cash, cash equivalents, available
for sale marketable securities and any future financing requirements. Interest
rate risks related to marketable securities are managed by managing maturities
in our marketable securities portfolio.
We have concluded that the fair market value of our investment portfolio or
related income would not be significantly impacted by changes in interest rates
due to the nature of our marketable securities, which do not exceed fiscal 2003
and have primarily fixed interest rates.
The following table presents the future principal cash flows or amounts and
related weighted average interest rates expected by year for our existing cash
and cash equivalents, marketable securities and long-term investments.
2002 2003 TOTAL FAIR VALUE
------ ------ ------ ----------
(IN THOUSANDS)
Cash, cash equivalents............................ $4,052 $ -- $4,052 $4,052
Short-term marketable securities.................. $4,697 -- $4,697 $4,697
Weighted average interest rate.................... 5.47% -- -- --
Long-term marketable securities................... $ -- $3,616 $3,616 $3,616
Weighted average interest rate.................... -- 5.95% -- --
QUALITATIVE DISCLOSURES
Interest Rate Risk.
Our primary interest rate risk exposures relate to:
- The available for sale securities will fall in value if market interest
rates increase.
- The impact of interest rate movements on our ability to obtain adequate
financing to fund future operations.
We have the ability to hold at least a portion of the fixed income
investments until maturity and therefore would not expect the operating results
or cash flows to be affected to a significant degree by a sudden change in
market interest rates on our short and long term marketable securities
portfolio.
42
45
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Our consolidated financial statements and the independent auditors' report
appear on pages F-1 through F-22 of this Report. See Item 14 for an index of
financial statements and supplementary data.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
Not applicable.
43
46
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
The information required by this item concerning our directors is
incorporated by reference from the sections captioned "Election of Directors"
and "Section 16(a) Beneficial Ownership Reporting Compliance" contained in the
Company's Proxy Statement related to the 2001 Annual Meeting of Shareholders to
be held August 16, 2001, to be filed by us within 120 days of the end of our
fiscal year pursuant to General Instruction G(3) of Form 10-K (the "Proxy
Statement"). Certain information required by this item concerning executive
officers set forth in Part I of this Report under information required
"Business -- Executive Officers" and certain other information required by this
item is incorporated by reference from the section captioned "Section 16(a)
Beneficial Ownership Reporting Compliance" contained in the Proxy Statement.
ITEM 11. EXECUTIVE COMPENSATION
The information required by this item is incorporated by reference from the
section captioned "Executive Compensation and Other Matters" contained in the
Proxy Statement.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The information required by this item is incorporated by reference from the
section captioned "Record Date and Principal Share Ownership" contained in the
Proxy Statement.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
The information required by this item is incorporated by reference from the
sections captioned "Compensation Committee Interlocks and Insider Participation"
and "Certain Transactions" contained in the Proxy Statement.
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K
(a)(1) Financial Statements
The following consolidated financial statements are filed as part of this
Report:
PAGE
----
Report of Independent Accountants........................... F-1
Consolidated Balance Sheets................................. F-2
Consolidated Statements of Operations....................... F-3
Consolidated Statement of Changes in Shareholders' Equity... F-4
Consolidated Statements of Cash Flows....................... F-5
Notes to Consolidated Financial Statements.................. F-6
(a)(2) Financial Statement Schedules
Schedule II -- Valuation and Qualifying Accounts.......... F-20
All other schedules are omitted because they are not applicable or the
required information is shown in the consolidated financial statements or notes
thereto.
44
47
(a)(3) Exhibits
3.1(1) Restated Articles of Incorporation of Registrant
3.2(2) Bylaws of Registrant, as amended
4.2(3) Preferred Share Rights Agreement dated January 22, 1997
between Registrant and Chase Mellon Shareholder Services,
L.L.C., including the Certificate of Determination, the form
of Rights Certificate and Summary of Rights attached thereto
as Exhibits A, B and C, respectively
10.1(4) 1988 Stock Incentive Program and forms of agreements
thereunder
10.2(5) 1992 Employee Stock Purchase Plan
10.3(2) Standard Industrial Lease Agreement between Registrant and
Sunlife Assurance Company of Canada dated October 22, 1989
10.3.1(6) First Amendment to Standard Industrial Lease Agreement
between Registrant and Sunlife Assurance Company of Canada
dated April, 1995
10.4(2) Forms of Indemnification Agreements between Registrant and
its officers and its directors
10.5 Reserved
10.6 Reserved
10.6.1 Reserved
10.7 Reserved
10.7.1 Reserved
10.8 Reserved
10.9 Reserved
10.10 Reserved
10.11.1 Reserved
10.11.2 Reserved
10.11.3 Reserved
10.11.4 Reserved
10.11.5 Reserved
10.11.6 Reserved
10.11.7 Reserved
10.12 Reserved
10.13 Reserved
10.14 Reserved
10.15 Reserved
10.16 Reserved
10.17.1(7) Letter Agreement effective December 20, 1996 by and between
Wells Fargo Bank and Registrant
10.17.2(7) Revolving Line of Credit Note effective December 20, 1996 by
and between Wells Fargo Bank and Registrant
10.17.3(7) General Pledge Agreement effective December 20, 1996 by and
between Wells Fargo Bank and Registrant
10.17.4(8) Revolving Line of Credit Note effective November 30, 1997 by
and between Wells Fargo Bank and Registrant
10.17.5(9) Revolving Line of Credit Note effective November 30, 1998 by
and between Wells Fargo Bank and Registrant
10.17.6(10) Revolving line of Credit Note Effective November 30, 1999 by
and between Wells Fargo Bank and Registrant
10.17.7(11) Revolving line of Credit Note effective May 1, 2000 by and
between Wells Fargo Bank and Registrant
10.18 Reserved
10.19 Reserved
10.20(12) 1997 Stock Incentive Program and Form of Agreement
thereunder
45
48
10.21(13) 1999 Nonstatutory Stock Option Plan and Form of Agreement
thereunder
10.21.1(14) Distribution Agreement between Registrant and McKesson Drug
Company dated August 18, 1998
10.21.2(14) Distribution Agreement between Registrant and Bergen
Brunswig Corporation dated July 20, 1998
10.22 Reserved
10.23(15) Employment Agreement between Registrant and Robert J.
Dominici dated July 15, 1998
10.24(16) Employment Agreement between Registrant and Jeffrey S. Aroy
dated September 3, 1999
10.25(11) Employment Agreement between Registrant and Thomas E. Worthy
dated August 6, 1999
10.26(11) Employment Agreement between Registrant and Terry L.
Wassmann dated March 28, 2000
10.27(11) Employment Agreement between Registrant and Kevin R.
Stromberg dated March 27, 2000
10.28(11) Employment Agreement between Registrant and Timothy I. Still
dated October 6, 1999
10.29(17) 2000 Stock Incentive Program and Form of Agreement
thereunder
10.30* Letter Agreement between Registrant and GMR Marketing, Inc.
dated January 23, 2001
10.31 Amendment to the Letter Agreement between Registrant and GMR
Marketing, Inc. dated April 30, 2001
10.32 Employment Agreement between Registrant and William W. Burke
dated March 14, 2001
10.33 Lease Agreement between Registrant and Terradev Jefferson
LLC dated July 28, 2000
10.34 Second Amendment to Standard Industrial Lease Agreement
between Registrant and Sunlife Assurance Company of Canada
dated March 17, 1995
10.35 Third Amendment to Standard Industrial Lease Agreement
between Registrant and Sunlife Assurance Company of Canada
dated January 27, 1997
10.36 Fourth Amendment to Standard Industrial Lease Agreement
between Registrant and The BIV Group (successor-in-interest
to Sunlife Assurance Company of Canada) dated March 3, 2000
10.3.2 Reserved
10.3.3 Reserved
21.1 Subsidiaries
23.1 Consent of Independent Accountants
---------------
* Confidential treatment has been requested from the Securities and Exchange
Commission with respect to certain portions of this exhibit. The redacted
portions have been filed separately with the Securities and Exchange
Commission.
(1) Incorporated by reference to exhibits filed with Registrant's Registration
Statement on Form S-1 (No. 33-54300) as declared effective by the
Securities and Exchange Commission on December 16, 1992.
(2) Incorporated by reference to exhibits filed with Registrant's Registration
Statement on Form S-1 (No. 33-47603) as declared effective by the
Securities and Exchange Commission on June 26, 1992.
(3) Incorporated by reference to exhibits filed with Registrant's Registration
Statement on Form 8-A (No. 000-20198) as declared effective by the
Securities and Exchange Commission on March 27, 1997.
(4) Incorporated by reference to exhibits filed with Registrant's Registration
Statement on Form S-8 (No. 333-22475) as declared effective by the
Securities and Exchange Commission on February 28, 1997.
(5) Incorporated by reference to exhibits filed with Registrant's Registration
Statement on Form S-8 (No. 333-38147) as declared effective by the
Securities and Exchange Commission on October 17,
46
49
1997, as amended by Registrant's Registration Statement on Form S-8 (No.
333-38147) as declared effective by the Securities and Exchange Commission
on October 17, 1997, as amended by Registrant's Registration Statement on
Form S-8 (No. 333-44980) as declared effective by the Securities and
Exchange Commission on August 31, 2000.
(6) Incorporated by reference to exhibits filed with Registrant's Quarterly
Report on Form 10-Q for the quarter ended June 30, 1995.
(7) Incorporated by reference to exhibits filed with Registrant's Quarterly
Report on Form 10-Q for the quarter ended December 27, 1996.
(8) Incorporated by reference to exhibits filed with Registrant's Quarterly
Report on Form 10-Q for the quarter ended December 26, 1997.
(9) Incorporated by reference to exhibits filed with Registrant's Quarterly
Report on Form 10-Q for the quarter ended December 25, 1998.
(10) Incorporated by reference to exhibits filed with Registrant's Quarterly
Report on Form 10-Q for the quarter ended December 24, 1999.
(11) Incorporated by reference to exhibits filed with Registrant's Annual Report
on Form 10-K for the fiscal year ended March 31, 2000.
(12) Incorporated by reference to exhibits filed with Registrant's Registration
Statement on Form S-8 (No. 333-38151) as declared effective by the
Securities and Exchange Commission on October 17, 1997.
(13) Incorporated by reference to exhibits filed with Registrant's Registration
Statement on Form S-8 (No. 333-94503) as declared effective by the
Securities and Exchange Commission on January 12, 2000.
(14) Incorporated by reference to exhibits filed with Registrant's Quarterly
Report on Form 10-Q for the quarter ended September 25, 1998.
(15) Incorporated by reference to exhibits filed with Registrant's Quarterly
Report on Form 10-Q for the quarter ended June 25, 1999.
(16) Incorporated by reference to exhibits filed with Registrant's Quarterly
Report on Form 10-Q for the quarter ended September 24, 1999.
(17) Incorporated by reference to exhibits filed with Registrant's Registration
Statement on Form S-8 (333-44980) as declared effective by the Securities
and Exchange Commission on August 31, 2000.
(b) Reports on Form 8-K. The Company did not file any reports on Form 8-K
during the quarter ended March 30, 2001.
(c) Exhibits. See Item 14(a)(3) above.
(d) Financial Statement Schedules. See Item 14(a)(2) above.
47
50
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, as amended, the Registrant has duly caused this Report to
be signed on its behalf by the undersigned, thereunto duly authorized.
CHOLESTECH CORPORATION
By: /s/ WARREN E. PINCKERT II
------------------------------------
Warren E. Pinckert II
President, Chief Executive Officer
and Director
Date: June 14, 2001
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature
appears below constitutes and appoints Warren E. Pinckert II and William W.
Burke, and each of them, his or her true and lawful attorneys-in-fact and
agents, each with full power of substitution and resubstitution, to sign any and
all amendments (including post-effective amendments) to this Annual Report on
Form 10-K and to file the same, with all exhibits thereto and other documents in
connection therewith, with the Securities and Exchange Commission, granting unto
said attorney-in-fact and agents, and each of them, full power and authority to
do and perform each and every act and thing requisite and necessary to be done
in connection therewith, as fully to all intents and purposes as he or she might
or could do in person, hereby ratifying and confirming all that said
attorneys-in-fact and agents, or their substitute or substitutes, or any of
them, shall do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities and Exchange Act of 1934, as
amended, this Report has been signed below by the following persons on behalf of
the Registrant and in the capabilities and on the dates indicated:
SIGNATURE TITLE DATE
--------- ----- ----
/s/ WARREN E. PINCKERT II President, Chief Executive Officer June 14, 2001
------------------------------------------------ and Director (Principal Executive
(Warren E. Pinckert II) Officer)
/s/ WILLIAM W. BURKE Vice President of Finance, Chief June 14, 2001
------------------------------------------------ Financial Officer, Treasurer and
(William W. Burke) Secretary
(Principal Financial and Accounting
Officer)
/s/ JOHN H. LANDON Director June 14, 2001
------------------------------------------------
(John H. Landon)
/s/ MICHAEL D. CASEY Director June 14, 2001
------------------------------------------------
(Michael D. Casey)
/s/ JOHN L. CASTELLO Director June 14, 2001
------------------------------------------------
(John L. Castello)
/s/ MOLLY J. COYE Director June 14, 2001
------------------------------------------------
(Molly J. Coye)
/s/ LARRY Y. WILSON Director June 14, 2001
------------------------------------------------
(Larry Y. Wilson)
48
51
REPORT OF INDEPENDENT ACCOUNTANTS
To the Board of Directors and
Shareholders of Cholestech Corporation
In our opinion, the consolidated financial statements listed in the index
appearing under Item 14(a)(1) present fairly, in all material respects, the
financial position of Cholestech Corporation and its subsidiaries at March 30,
2001 and March 31, 2000, and the results of their operations and their cash
flows for each of the three years in the period ended March 30, 2001 in
conformity with accounting principles generally accepted in the United States of
America. In addition, in our opinion, the financial statement schedule listed in
the index appearing under Item 14(a)(2) presents fairly, in all material
respects, the information set forth therein when read in conjunction with the
related consolidated financial statements. These financial statements and
financial statement schedule are the responsibility of the Company's management;
our responsibility is to express an opinion on these financial statements and
financial statement schedule based on our audits. We conducted our audits of
these statements in accordance with auditing standards generally accepted in the
United States of America which require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements, assessing
the accounting principles used and significant estimates made by management, and
evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for our opinion.
/s/ PRICEWATERHOUSECOOPERS LLP
San Jose, California
April 20, 2001, except for the fourth paragraph
of Note 5, which is as of June 14, 2001
F-1
52
CHOLESTECH CORPORATION
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT SHARE DATA)
MARCH 30, 2001 MARCH 31, 2000
-------------- --------------
ASSETS
Current assets:
Cash and cash equivalents................................. $ 4,052 $ 6,959
Restricted cash........................................... -- 1,000
Marketable securities..................................... 4,697 2,850
Accounts receivable, net.................................. 3,014 1,839
Inventories, net.......................................... 3,658 3,714
Prepaid expenses and other assets......................... 717 902
-------- --------
Total current assets.............................. 16,138 17,264
Property and equipment, net................................. 7,777 8,309
Long-term investments....................................... 3,616 3,932
Goodwill, net............................................... 3,143 2,661
Other assets, net........................................... 68 52
-------- --------
Total assets...................................... $ 30,742 $ 32,218
======== ========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses..................... $ 3,893 $ 3,788
Accrued payroll and benefits.............................. 1,900 1,563
Other liabilities......................................... 91 391
-------- --------
Total current liabilities......................... 5,884 5,742
-------- --------
Commitments and contingencies (Note 5)
Shareholders' equity:
Preferred Stock, no par value; 5,000,000 shares
authorized, no shares issued and outstanding........... -- --
Common Stock, no par value; 25,000,000 shares authorized;
12,100,647 and 11,921,251 shares issued and outstanding
at March 30, 2001 and March 31, 2000................... 72,819 71,959
Accumulated other comprehensive income (loss)............. 69 (59)
Accumulated deficit....................................... (48,030) (45,424)
-------- --------
Total shareholders' equity........................ 24,858 26,476
-------- --------
Total liabilities and shareholders' equity........ $ 30,742 $ 32,218
======== ========
See accompanying notes to consolidated financial statements.
F-2
53
CHOLESTECH CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
FISCAL YEAR ENDED
-----------------------------------
MARCH 30, MARCH 31, MARCH 26,
2001 2000 1999
--------- --------- ---------
Revenue:
Product................................................... $32,489 $27,000 $22,032
Service................................................... 4,514 549 --
------- ------- -------
Total revenue..................................... 37,003 27,549 22,032
------- ------- -------
Cost of revenue:
Product................................................... 14,055 11,056 10,252
Service................................................... 1,225 155 --
------- ------- -------
Total cost of revenue............................. 15,280 11,211 10,252
------- ------- -------
Gross profit................................................ 21,723 16,338 11,780
------- ------- -------
Operating expenses:
Sales and marketing....................................... 11,388 7,032 6,606
Research and development.................................. 2,586 3,021 2,703
Website and related costs................................. 1,952 -- --
General and administrative................................ 5,079 3,510 2,381
Goodwill amortization..................................... 709 100 --
Legal and other related................................... 1,312 219 826
Impairment charge......................................... 1,958 -- --
------- ------- -------
Total operating expenses.......................... 24,984 13,882 12,516
------- ------- -------
Income (loss) from operations............................... (3,261) 2,456 (736)
Interest and other income, net.............................. 655 805 663
------- ------- -------
Income (loss) before taxes.................................. (2,606) 3,261 (73)
Provision for income taxes.................................. -- 129 --
------- ------- -------
Net income (loss)........................................... $(2,606) $ 3,132 $ (73)
======= ======= =======
Net income (loss) per share:
Basic..................................................... $ (0.22) $ 0.27 $ (0.01)
======= ======= =======
Diluted................................................... $ (0.22) $ 0.26 $ (0.01)
======= ======= =======
Shares used to compute net income (loss) per share:
Basic..................................................... 12,046 11,724 11,484
======= ======= =======
Diluted................................................... 12,046 11,920 11,484
======= ======= =======
See accompanying notes to consolidated financial statements.
F-3
54
CHOLESTECH CORPORATION
CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY
(IN THOUSANDS, EXCEPT SHARE DATA)
ACCUMULATED
OTHER
COMMON STOCK COMPREHENSIVE
-------------------- INCOME ACCUMULATED
SHARES AMOUNT (LOSS) DEFICIT TOTAL
---------- ------- ------------- ----------- -------
Balance at March 27, 1998................ 11,402,084 $69,880 $ 49 $(48,483) $21,446
Net loss................................. -- -- -- (73) (73)
Change in unrealized gain on
available-for-sale securities.......... -- -- (35) -- (35)
-------
Comprehensive loss....................... (108)
-------
Issuance of Common Stock pursuant to
employee stock purchase plan and
exercise of stock options.............. 116,156 431 -- -- 431
---------- ------- ---- -------- -------
Balance at March 26, 1999................ 11,518,240 70,311 14 (48,556) 21,769
-------
Net income............................... -- -- -- 3,132 3,132
Change in unrealized gain on
available-for-sale securities.......... -- -- (73) -- (73)
-------
Comprehensive income..................... 3,059
-------
Issuance of Common Stock pursuant to
employee stock purchase plan and
exercise of stock options.............. 403,011 1,426 -- -- 1,426
Stock compensation expense............... -- 132 -- -- 132
Warrants issued pursuant to acquisition
of Health Net.......................... -- 90 -- -- 90
---------- ------- ---- -------- -------
Balance at March 31, 2000................ 11,921,251 71,959 (59) (45,424) 26,476
-------
Net loss................................. -- -- -- (2,606) (2,606)
Change in unrealized gain on
available-for-sale securities.......... -- -- 128 -- 128
-------
Comprehensive loss....................... (2,478)
-------
Issuance of Common Stock pursuant to
employee stock purchase plan and
exercise of stock options.............. 128,386 560 -- -- 560
Issuance of Common Stock pursuant to
Health Net purchase.................... 51,010 300 -- -- 300
---------- ------- ---- -------- -------
Balance at March 30, 2001................ 12,100,647 $72,819 $ 69 $(48,030) $24,858
========== ======= ==== ======== =======
See accompanying notes to consolidated financial statements.
F-4
55
CHOLESTECH CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
FISCAL YEAR ENDED
-----------------------------------
MARCH 30, MARCH 31, MARCH 26,
2001 2000 1999
--------- --------- ---------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)........................................ $ (2,606) $ 3,132 $ (73)
Adjustments to reconcile net income (loss) to net cash
provided by (used in) operating activities:
Depreciation and amortization......................... 3,471 1,597 1,112
Change in allowance for doubtful accounts............. 224 269 2
Change in inventory reserve........................... 107 57 152
Change in allowance for sales returns................. -- 83 --
Impairment charge..................................... 1,958 -- --
Stock compensation expense............................ -- 132 --
Changes in assets and liabilities:
Accounts receivable................................. (1,394) 618 1,154
Inventories......................................... (51) 816 (1,378)
Prepaid expenses and other assets................... 188 (756) 14
Other assets........................................ (21) -- 15
Accounts payable and accrued liabilities............ 85 1,944 (1,570)
Accrued payroll and benefits........................ 337 573 (146)
Other liability..................................... -- -- (112)
-------- -------- --------
Net cash provided by (used in) operating
activities..................................... 2,298 8,465 (830)
-------- -------- --------
CASH FLOWS FROM INVESTING ACTIVITIES:
Restricted cash.......................................... 1,000 (1,000) --
Purchases of marketable securities....................... (11,166) (26,661) (19,225)
Maturities of marketable securities...................... 9,763 25,704 22,913
Acquisition of Health Net assets......................... (1,179) (2,298) --
Purchase of property and equipment....................... (4,183) (4,206) (2,890)
-------- -------- --------
Net cash provided by (used in) investing activities... (5,765) (8,461) 798
-------- -------- --------
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of common stock................................. 560 1,426 431
-------- -------- --------
Net cash provided by financing activities............. 560 1,426 431
-------- -------- --------
Net change in cash and cash equivalents.................. (2,907) 1,430 399
Cash and cash equivalents at beginning of year........... 6,959 5,529 5,130
-------- -------- --------
Cash and cash equivalents at end of year................. $ 4,052 $ 6,959 $ 5,529
======== ======== ========
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes................................. $ -- $ 110 $ --
Accrued liability for common stock to be issued for Health
Net acquisition.......................................... -- 300 --
Common stock issued for Health Net acquisition............. 300 -- --
See accompanying notes to consolidated financial statements.
F-5
56
CHOLESTECH CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. THE COMPANY AND A SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Operations
Cholestech Corporation (the "Company") was incorporated February 2, 1988.
Through March 30, 2001 the Company operated in three business segments:
- Diagnostic Products -- which develops, manufactures and markets the
Cholestech L-D-X(R) System (the "L-D-X System") which performs
near-patient diagnostic testing to assist in assessing for risk of
certain cholesterol-related diseases and to assist in the monitoring of
therapy to treat those diseases.
- WellCheck(TM) -- which conducts consumer testing within the United States
to assess for risk of certain cholesterol-related diseases and to assist
in the monitoring of therapy to treat those diseases.
- WellCheck.com -- which provides interactive tools to consumers through
the Internet to better assess for risk of certain cholesterol-related
diseases and to monitor and motivate personal health management of those
diseases.
Beginning in fiscal 2002, the Company will combine WellCheck and
WellCheck.com and operate in two business segments.
Summary of significant accounting policies
Fiscal year end
The Company's fiscal year is a 52 - 53 week period ending on the last
Friday in March. Fiscal 2001 was comprised of 52 weeks, fiscal 2000 was
comprised of 53 weeks, and fiscal 1999 was comprised of 52 weeks.
Principles of consolidation
The consolidated financial statements include the accounts of the Company
and its wholly owned subsidiaries. All significant intercompany transactions and
balances have been eliminated.
Revenue recognition
The Company has adopted the provisions of Staff Accounting Bulletin ("SAB")
No. 101 "Revenue Recognition in Financial Statements" and believes that its
current and historical revenue recognition policy is in compliance with the SAB.
The Company has also applied Emerging Issues Task Force Issue No. ("EITF") 00-10
"Accounting for Shipping and Handling Fees and Costs" retroactively to all
periods presented. As a result, for all periods presented, amounts billed to
customers relating to shipping and handling have been classified as revenue and
all related costs are classified as cost of sales.
Revenue from product sales is recognized upon receipt of a purchase order
and product shipment provided no significant obligations remain and collection
of the receivable is deemed probable.
Revenue associated with testing services is recognized upon completion of
the services to be performed under the contract when all obligations are
satisfied, and collection of the receivables is deemed probable.
Cash and cash equivalents and marketable securities
The Company considers all highly liquid investments with maturities of
three months or less at the date of purchase to be cash equivalents; other
investments with maturities of less than one year are classified as short-term
marketable securities. The Company has established policies, which limit the
type, credit quality and length of maturity of the securities in which it
invests. Cash equivalents and marketable securities at March 30, 2001 consist
principally of investments in money market funds, commercial paper and U.S.
government-agency obligations. Marketable securities are classified as
available-for-sale and are carried at
F-6
57
CHOLESTECH CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
their market value at the balance sheet date. Realized gains and losses on sales
of all such securities are reported in earnings and computed using the specific
identification cost method. Unrealized gains and losses on such securities are
included in accumulated comprehensive income/(loss) in shareholders' equity. All
investments with maturity dates greater than 365 days are classified as
non-current.
There was $69,000 in unrealized gains as of March 30, 2001 included in the
comprehensive income in stockholders' equity and $59,000 in unrealized losses as
of March 31, 2000.
The cost and fair market value of available-for-sale securities at March
30, 2001 are as follows (in thousands):
UNREALIZED
COST GAIN FAIR VALUE MATURITY DATE
------ ---------- ---------- -------------
Short-term marketable
securities
Commercial paper............ $4,675 $22 $4,697 April - October 2001
====== === ======
Long-term marketable
securities
Corporate bonds............. $1,034 $27 $1,061 May 2002
Government agency........... 2,535 20 2,555 November 2002 - February 2003
------ --- ------
$3,569 $47 $3,616
====== === ======
The cost and fair market value of available-for-sale securities at March
31, 2000 are as follows (in thousands):
UNREALIZED
COST GAIN FAIR VALUE
------ ---------- ----------
Short-term marketable securities
Commercial paper................................... $1,002 $ (4) $ 998
Government agency.................................. 1,869 (17) 1,852
------ ---- ------
$2,871 $(21) $2,850
====== ==== ======
Long-term marketable securities
Corporate bonds.................................... $3,970 $(38) $3,932
====== ==== ======
Restricted cash
There was no restricted cash as of March 30, 2001 as the Health Net
acquisition was completed. In fiscal 2000, the Company reported restricted cash
of $1.0 million as part of the Health Net purchase price.
Certain risks and uncertainties
Financial instruments that potentially subject the Company to credit risk
consist of cash equivalents, marketable securities and accounts receivable. Cash
equivalents and marketable securities are maintained with a high credit quality
institution, and the composition and maturities of the investments are regularly
monitored by management. Generally, these securities are highly liquid and may
be redeemed on demand and, therefore, have minimal risk associated with them.
The Company has not experienced any material losses on its investments.
The Company's trade accounts receivable generally consist of a large number
of small customers. Concentration of credit risk with respect to trade accounts
receivable is considered to be limited due to this customer base and the
diversity of the Company's geographic sales areas. The Company performs ongoing
credit evaluations of its customers' financial condition and, generally,
requires no collateral. The Company maintains a provision for potential credit
losses and such amounts, in the aggregate, have not been material.
F-7
58
CHOLESTECH CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
Provision is concurrently made for estimated product returns, which historically
have been immaterial. In fiscal 2001 one customer accounted for $6.1 million or
16.4% of total revenue, all of which related to our diagnostic products business
compared to fiscal 2000 when two customers accounted for $2.5 million or 16.9%
and $2.0 million or 11.0% of total revenue, respectively. At March 30, 2001 a
single customer accounted for $876,000 or 32.4% of the total accounts
receivable. Two customers accounted for $218,000 or 11.9% and $185,000 or 10.1%
of total accounts receivable at March 31, 2000.
Inventories
Inventories are stated at the lower of cost or market, cost being
determined using the first-in, first-out (FIFO) method. Cost includes direct
materials, direct labor and manufacturing overhead.
Property and equipment
Property and equipment are stated at cost. Depreciation is computed using
the straight-line method over the estimated useful lives of the related assets,
which range from two to five years. Leasehold improvements are amortized over
their estimated useful lives, not to exceed the term of the related lease. The
cost of additions and improvements is capitalized while maintenance and repairs
are charged to expense as incurred. Upon sale or retirement, the asset's cost
and related accumulated depreciation are removed from the accounts and any
related gain or loss is reflected in operations.
Impairment of long-lived assets
The Company identifies and records impairment losses on long-lived assets
when events and circumstances indicate that the future value of such assets is
less than the carrying amounts of those assets. Recoverability is measured by
comparison of the assets' carrying amount to future net undiscounted cash flows
the assets are expected to generate. If such assets are considered to be
impaired, the impairment to be recognized is measured by the amount by which the
carrying amount of the assets exceeds their projected discounted future net cash
flows.
Goodwill
Goodwill represents the excess of purchase price paid over the value
assigned to the net tangible assets of businesses acquired. Goodwill is
amortized on a straight-line basis over five years. Periodically, the Company
reviews the recoverability of goodwill. The measurement of possible impairment
is based primarily on the ability to recover the balance of the goodwill from
expected future operating cash flows on an undiscounted basis. Amortization
expense was $709,000 and $100,000 in fiscal 2001 and 2000, respectively.
A proposed FASB Statement of Financial Accounting Standards on Business
Combinations, which would eliminate goodwill amortization, could reduce the
total annual amortization expense in periods subsequent to issuance of the final
standard.
Website development costs and other internally developed software
The Company accounts for website development costs in accordance with the
AICPA Statement of Position ("SOP") 98-1, "Accounting for the Costs of Computer
Software Developed or Obtained for Internal Use." The Company has also adopted
EITF No. 00-2 "Accounting for the Costs of Developing a Website".
Website development costs consist of external and internal costs incurred
to purchase and implement the website software and significant enhancements used
in the Company's WellCheck.com business. These costs are capitalized and
amortized using the straight-line method over the estimated useful life of the
asset, usually three years. In the fourth quarter of fiscal 2001 it was
determined that the net book value of the Company's capitalized website costs of
$1.96 million were impaired. Internally developed software consists primarily of
F-8
59
CHOLESTECH CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
Test Event Activity Management System ("TEAMS") software development cost of
$558,000 was capitalized at March 30, 2001.
Internal and external costs of developing website content are expensed as
incurred and included in the accompanying consolidated statement of operations
in accordance with SOP 98-1.
Research and development
Research and development costs are expensed as incurred.
Warranties
The Company's products are generally under warranty against defects in
material and workmanship for a period of up to one year. The Company accrues for
estimated future warranty costs at the time of sale. The Company is currently
dependent on a sole or limited number of suppliers for certain key components
used in its products, which may cause shortages that limit production capacity.
There can be no assurance that such shortages will not adversely affect future
operating results.
Advertising costs
The cost of advertising is expensed as incurred. Advertising expenses were
$472,000, $48,000 and $169,000 for fiscal 2001, 2000 and 1999, respectively.
Income taxes
The Company uses the asset and liability method of accounting for income
taxes, which requires the recognition of deferred tax liabilities and assets for
the expected future tax consequences of temporary differences between the
financial reporting and income tax bases of assets and liabilities.
Net income (loss) per share
Basic earnings per share is computed by dividing net income (loss)
(numerator) by the weighted average number of common shares outstanding
(denominator) during the period. Diluted earnings per share gives effect to all
potential common stock outstanding during a period, if dilutive. The following
table reconciles the numerator (net income or loss) and denominator (number of
shares) used in the basic and diluted per share computations.
NET INCOME
(LOSS) SHARES PER SHARE
------------ -------- -----------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
Fiscal year ended March 26, 1999:
Basic...................................... $ (73) 11,484 $(0.01)
Effect of dilutive securities.............. -- -- --
Diluted.................................... $ (73) 11,484 $(0.01)
Fiscal year ended March 31, 2000:
Basic...................................... $ 3,132 11,724 $ 0.27
Effect of dilutive securities.............. -- 196 (0.01)
Diluted.................................... $ 3,132 11,920 $ 0.26
Fiscal year ended March 30, 2001:
Basic...................................... $(2,606) 12,046 $(0.22)
Effect of dilutive securities.............. -- -- --
Diluted.................................... $(2,606) 12,046 $(0.22)
F-9
60
CHOLESTECH CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
Due to the net loss incurred during fiscal 2001, options to purchase
2,711,304 shares of common stock were considered anti-dilutive at March 30,
2001. At March 31, 2000, options to purchase 1,222,484 shares of common stock
were considered anti-dilutive because the respective exercise prices were
greater than the average fair market value of the common stock. Due to the net
loss incurred during fiscal 1999, options to purchase 1,842,734 shares of common
stock were considered anti-dilutive at March 26, 1999.
Fair value of financial instruments
The carrying amounts of certain of our financial instruments including cash
and cash equivalents, accounts receivable and accounts payable approximate fair
value due to their short maturities.
Use of estimates
The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at
the date of the financial statements and the reported amounts of revenue and
expenses during the reporting period. Actual results could differ from those
estimates.
Accounting for stock-based compensation
The Company accounts for stock-based employee compensation arrangements in
accordance with provisions of Accounting Principles Board Opinion No. 25,
"Accounting for Stock Issued to Employees" ("APB 25") and complies with the
disclosure provisions of Statement of Financial Accounting Standards No. 123,
"Accounting for Stock-Based Compensation" ("SFAS 123").
Under APB 25, compensation expense for grants to employees is based on the
difference, if any, on the date of the grant, between the fair market value of
the Company's stock and the option exercise price. SFAS 123 defines a "fair
value" based method of accounting for an employee stock option or similar equity
investment. The pro forma disclosure of the difference between compensation
expense included in net loss and the related cost measured by the fair value
method is presented in Note 6.
The Company also adopted FASB Interpretation No. 44, ("FIN 44"),
"Accounting for Certain Transactions Involving Stock Compensation -- an
Interpretation of APB 25." The adoption of FIN 44 had no material impact on
financial reporting and related disclosures of the Company.
The Company accounts for equity instruments issued to non-employees in
accordance with the provisions of SFAS 123 and Emerging Issues Task Force Issue
No. 96-18, "Accounting for Equity Instruments that are Issued to Other Than
Employees for Acquiring, or in Conjunction with Selling Goods and Services," and
Financial Accounting Standards Board Interpretation No. 28, "Accounting for
Stock Appreciation Rights and Other Variable Stock Option or Award Plan" ("FIN
28").
Reclassifications
Certain financial statement items have been reclassified to conform to the
current year's format. These reclassifications had no impact on previously
reported results of operations.
Recent accounting pronouncements
In June 1998, the Financial Accounting Standards Board issued SFAS No. 133
"Accounting for Derivative Instruments and Hedging Activities," which
establishes accounting and reporting standards for derivative instruments and
hedging activities. It requires that an entity recognize all derivatives as
either assets or liabilities on the balance sheet and measure those instruments
at fair value. The Company, to date, has not
F-10
61
CHOLESTECH CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
engaged in derivative and hedging activities, and accordingly, does not believe
that the adoption of SFAS No. 133 will have a material impact on the financial
reporting and related disclosures of the Company. The Company will adopt SFAS
No. 133, as required by SFAS 137, "Accounting for Derivative Instruments and
Hedging Activities -- Deferral of the Effective Date of the FASB Statement No.
133," beginning with the first quarter of fiscal 2002.
In the first quarter of 2001, the Financial Accounting Standards Board
issued an Exposure Draft related to business combinations. If the final results
are adopted as proposed, as of January 1, 2002, the Company will no longer be
required to amortize goodwill as a charge to earnings. In addition, the Company
will be required to periodically review goodwill for potential impairment. If an
impairment is found to exist, a charge will be taken against earnings in the
Company's consolidated statement of operations. The Company cannot currently
determine the amount of an impairment charge, if any, that would be recorded
upon adoption.
2. IMPAIRMENT
The Company has been unable to generate significant revenues from website
and related databases which during the fourth quarter of fiscal 2001 prompted an
impairment review of certain capitalized costs. The Company calculated the
present value of expected cash flows for both capitalized website costs and
capitalized database costs over the remaining useful lives of these assets to
determine the fair value of the assets which provided the basis for measurement
of the impairment charge. This review indicated that the assets were fully
impaired. Accordingly, in the fourth quarter of fiscal 2001, the Company
recorded an impairment charge of $1.96 million in the WellCheck.com segment.
3. BALANCE SHEET COMPOSITION
Accounts receivable consist of (in thousands):
MARCH 30, 2001 MARCH 31, 2000
-------------- --------------
Accounts receivable............................. $3,188 $2,059
Less allowance for sales returns................ (83) (83)
Less allowance for doubtful accounts............ (91) (137)
------ ------
$3,014 $1,839
====== ======
Inventories consist of (in thousands), net:
MARCH 30, 2001 MARCH 31, 2000
-------------- --------------
Raw materials................................... $1,263 $1,258
Work-in-progress................................ 1,219 1,412
Finished goods.................................. 1,176 1,044
------ ------
$3,658 $3,714
====== ======
F-11
62
CHOLESTECH CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
Property and equipment consist of (in thousands):
MARCH 30, 2001 MARCH 31, 2000
-------------- --------------
Machinery equipment and software................ $ 9,447 $ 6,927
Furniture and fixtures.......................... 371 240
Computer equipment.............................. 2,528 1,734
Leasehold improvements.......................... 1,291 779
Construction-in-progress........................ 2,745 3,694
Website development costs....................... -- 1,994
------- -------
16,382 15,368
Less accumulated depreciation and
amortization.................................. (8,605) (7,059)
------- -------
$ 7,777 $ 8,309
======= =======
Depreciation expense of $2.8 million was incurred in fiscal 2001, $1.5
million in fiscal 2000 and $1.1 million in fiscal 1999. TEAMS software
development cost of $558,000 was capitalized at March 20, 2001 with an
accumulated amortization of $140,000.
Goodwill consists of (in thousands):
MARCH 30, 2001 MARCH 31, 2000
-------------- --------------
Cost............................................ $3,952 $2,761
Less accumulated amortization................... (809) (100)
------ ------
$3,143 $2,661
====== ======
Accounts payable and accrued liabilities consist of (in thousands):
MARCH 30, 2001 MARCH 31, 2000
-------------- --------------
Trade accounts payable.......................... $1,842 $2,823
Accrued legal expenses.......................... 1,006 --
Accrued royalties............................... 155 182
Other accrued liabilities....................... 890 783
------ ------
$3,893 $3,788
====== ======
4. BORROWING ARRANGEMENTS
In May 2000, the Company entered into a new agreement with its primary bank
for an $8 million revolving line of credit (the "line of credit") replacing its
prior agreement for a $3 million revolving line of credit. While the new line of
credit is in effect, the Company is required to maintain on deposit with the
bank assets with a collective value, as defined in the line of credit agreement,
equivalent to no less than 100% of the outstanding principal balance. Amounts
outstanding under the line of credit bear interest at the bank's prime rate. The
line of new credit agreement expires on May 1, 2002. As of March 30, 2001 and
March 31, 2000, there were no borrowings outstanding under the lines of credit.
5. COMMITMENTS AND CONTINGENCIES
Leases
We lease office and laboratory facilities under non-cancelable operating
leases, which originally expired between March and June 2000. The lease for the
Company's approximately 40,000 square foot headquarters facility has been
extended and currently expires in March 2002. A second approximately 7,200
square foot facility in Hayward was leased during fiscal 2001 which will expire
in October 2003. In November 2000, 5,100
F-12
63
CHOLESTECH CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
square feet of office space in Oakland, California was leased for a five year
term. Rent expense was $609,000, $374,000 and $409,000 for fiscal 2001, 2000 and
1999, respectively.
Future minimum payments required under the Company's non-cancelable
operating leases at March 30, 2001 were $688,000, $258,000, $216,000, $192,000
and $115,000 for fiscal years 2002, 2003, 2004, 2005 and 2006, respectively.
License and development agreements
The Company has obtained rights to use certain technology in manufacturing
its products. The related agreement, which expires in 2006, requires the Company
to pay a 2.0% royalty on net sales of the applicable products. Total royalty
expense for fiscal 2001, 2000 and 1999 was $490,000, $456,000 and $379,000,
respectively and was charged to cost of product revenue.
Litigation
On February 5, 1999, a complaint entitled Ree v. Pinckert, et al., No.
C99-0562 (PJH) was filed in the United States District Court for the Northern
District of California. The action is a putative class action and the Complaint
alleges that our company and certain of its current and former officers violated
the federal securities laws by making false and misleading statements concerning
our Company and its business during the period of June 28, 1996 through June 25,
1998. On June 14, 2001, we executed an agreement in principle with plaintiffs to
resolve this matter for a payment $3 million by our insurance carrier. We
recorded a $1.3 million charge during the fiscal year ended March 30, 2001 for
legal fees and insurance costs related to resolving this matter. The settlement
is contingent on Court approval.
The Company is subject to various legal claims and assessments in the
ordinary course of business, none of which are expected by management to result
in a material adverse effect on the consolidated financial statements.
6. SHAREHOLDERS' EQUITY
Preferred stock
The Company is authorized to issue 5,000,000 shares of preferred stock. The
board of directors has authority to issue the preferred stock in one or more
series and to fix the price, rights preferences, privileges and restrictions
thereof, including the dividend rights, dividend rates, conversion rights,
voting rights terms of redemption, redemption prices, liquidation preferences,
and the number of shares constituting a series or the designation of such
series, without any further vote or action by the Company's shareholders. In
connection with the Company's shareholder rights plan, 25,000 shares of the
preferred stock have been designated Series A participating preferred stock.
None of the Shares of Series A participating preferred stock were outstanding as
of March 30, 2001, nor was there any activity relating to preferred stock during
the three year period ended March 30, 2001.
Stock incentive program
The 1988 Stock Incentive Program (the "1988 Program") provided that
incentive stock options ("ISOs") and nonqualified stock options ("NSOs") for
shares of common stock could be granted to employees and consultants of the
Company. In accordance with the 1988 Program, the exercise price could not be
less than 100% and 85% of the fair market value of common stock on the date of
the grant for ISOs and NSOs, respectively. The 1988 Program provided that
options would be exercisable over a period not to exceed five years and a day.
Options vested over four years at a rate of at least 25% each year. Vesting of
individual option grants could be accelerated on the occurrence of certain
events as described in the stock option
F-13
64
CHOLESTECH CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
agreement. The 1988 Program expired in February 1998. There are no shares
available for future grant under the 1988 Program.
In August 1997, the shareholders approved the 1997 Stock Incentive Program
(the "1997 Program") which provides ISOs and NSOs for shares of common stock
which may be granted to employees and consultants of the Company. In accordance
with the 1997 Program, the exercise price may not be less than 100% of the fair
market value of common stock on the date of the grant for ISOs and NSOs,
respectively. The 1997 Program provides that options shall be exercisable over a
period not to exceed seven years and a day. Options vest over four years at a
rate of at least 25 percent each year. Vesting of individual option grants may
be accelerated on the occurrence of certain events as described in the stock
option agreement. There are no shares available for future grant under the 1997
Program.
In August 1999, the board of directors approved the 1999 Nonstatutory Stock
Option Plan (the "1999 Program") which provides NSOs for shares of common stock
which may be granted to employees and consultants of the Company. In accordance
with the 1999 Program, the exercise price may not be less than 100% of the fair
market value of common stock on the date of the grant for NSOs. The 1999 Program
provides that options shall be exercisable over a period not to exceed 10 years
and a day. Options vest over four years at a rate of at least 25% each year.
Vesting of individual options grants may be accelerated on the occurrence of
certain events as described in the stock option agreement. Pursuant to the terms
of the 1999 Program, 1,000,000 shares of common stock are reserved for future
issuance.
In August 2000, the shareholders approved the 2000 Stock Incentive Program
(the "2000 Program") which provides ISOs and NSOs for shares of common stock
which may be granted to employees and consultants of the Company. In accordance
with the 2000 Program, the exercise price may not be less than 100% of the fair
market value of common stock on the date of the grant for ISOs and NSOs. The
2000 Program provides that options shall be exercisable over a period not to
exceed 10 years. Options vest over four years at a rate of at least 25% each
year. Vesting of individual option grants may be accelerated on the occurrence
of certain events as described in the stock option agreement. Pursuant to the
terms of the 2000 Program, 590,000 shares of common stock are reserved for
future issuance.
Stock option activity under the programs is as follows:
WEIGHTED
AVERAGE
OUTSTANDING EXERCISE PRICE
OPTIONS PER SHARE
----------- --------------
Balance, March 27, 1998............................. 1,295,665 $5.41
Granted............................................. 982,386 6.73
Exercised........................................... (66,804) 3.39
Canceled............................................ (300,151) 6.47
---------
Balance, March 26, 1999............................. 1,911,096 5.99
Granted............................................. 691,105 5.83
Exercised........................................... (329,651) 3.87
Canceled............................................ (329,501) 7.55
---------
Balance, March 31, 2000............................. 1,943,049 6.03
Granted............................................. 1,000,887 6.72
Exercised........................................... (91,154) 4.02
Canceled............................................ (141,478) 7.49
---------
Balance, March 30, 2001............................. 2,711,304 6.28
=========
As of March 30, 2001, options for 20,056 and 320,988 shares of common stock
were available for future grant under the 1999 Program and 2000 Program,
respectively.
F-14
65
CHOLESTECH CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
The following table summarizes information about stock options outstanding
at March 30, 2001:
OPTIONS OUTSTANDING OPTIONS EXERCISABLE
--------------------------------------------- --------------------------
RANGE OF WEIGHTED AVG. WEIGHTED AVG. WEIGHTED AVG.
EXERCISE PRICES NUMBER CONTRACTUAL LIFE EXERCISE PRICE NUMBER EXERCISE PRICE
--------------- --------- ---------------- -------------- --------- --------------
$1.75 - $ 3.25... 152,445 3.0 $2.15 73,218 $2.13
$3.26 - $ 6.56... 1,530,878 4.4 5.18 1,006,652 5.13
$6.57 - $14.13... 1,027,981 7.0 8.52 320,839 9.83
--------- ---------
2,711,304 6.0 6.28 1,400,709 6.04
========= =========
Employee stock purchase plan
In April 1992, the Company adopted the Employee Stock Purchase Plan (the
"Stock Purchase Plan"), which reserved 75,000 shares of common stock to be
issued in accordance with the Internal Revenue Code under such terms as approved
by the board of directors. In August 1995, the shareholders approved an increase
in the number of shares reserved for issuance under the Stock Purchase Plan from
75,000 to 200,000. In August 1997, the shareholders approved an additional
increase in the number of shares reserved for issuance under the Stock Purchase
Plan from 200,000 to 400,000. In August 2000, the shareholders approved an
additional increase in the number of shares reserved for issuance under the
Stock Purchase Plan from 400,000 to 600,000. Under the terms of the Stock
Purchase Plan, employees can choose semi-annually to have up to 15% of their
compensation withheld to purchase shares of common stock. The purchase price is
equal to 85% of the lower of the closing price of the common stock on the NASDAQ
National Market on the day the Stock Purchase Plan period begins or ends. Under
the Stock Purchase Plan, the Company sold 37,232, 74,188 and 49,352 shares of
common stock to employees in fiscal 2001, 2000 and 1999, respectively.
Pro forma disclosures
Had compensation cost for the Company's stock option and stock purchase
plans been determined based on the fair market value of the options at the grant
dates, as prescribed in SFAS No. 123, the Company's net income (loss) and net
income (loss) per share would have been as follows:
FISCAL YEAR ENDED
------------------------------------------------
MARCH 30, 2001 MARCH 31, 2000 MARCH 26, 1999
-------------- -------------- --------------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
Net income (loss):
As reported........................ $(2,606) $3,132 $ (73)
Pro forma.......................... $(4,096) $2,284 $ (871)
Net income (loss) per share:
As reported -- basic............... $ (0.22) $ 0.27 $(0.01)
Pro forma -- basic................. $ (0.34) $ 0.19 $(0.08)
As reported -- diluted............. $ (0.22) $ 0.26 $(0.01)
Pro forma -- diluted............... $ (0.34) $ 0.19 $(0.08)
The fair value of each stock option is estimated on the date of the grant
using the Black-Scholes valuation model, with the following assumptions used for
grants during the applicable periods: dividend yield of 0.0% for all periods;
risk free interest rates of 5.9%, 5.7% and 5.3% for options granted during
fiscal 2001, 2000 and 1999, respectively; volatility factors of 88%, 93% and
93%, for options granted during fiscal 2001 2000 and 1999, respectively; and a
weighted average expected option term of 7.0 years, 6.7 years and 4.0 years for
fiscal 2001, 2000 and 1999 respectively. The weighted average per share value of
stock options granted in fiscal 2001, 2000 and 1999, was $5.37, $4.74 and $4.20
per share, respectively.
F-15
66
CHOLESTECH CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
The fair value of stock purchase rights is estimated using the
Black-Scholes valuation model with the following assumptions for fiscal 2001,
2000 and 1999, respectively; dividend yield of 0.0% for all periods; an expected
life of 6 months for all periods; expected volatility factors of 88%, 93% and
93% for fiscal 2001, 2000 and 1999, respectively. The weighted average per share
value of stock purchase rights granted in fiscal 2001 2000, and 1999, was $1.28,
$0.54 and $1.12, per share, respectively. The weighted average per share
exercise price of stock purchase rights granted in fiscal 2001, 2000 and 1999
was $5.05, $2.02 and $4.16, respectively.
The pro forma effect on net income (loss) and net income (loss) per share
for fiscal 2001, 2000 and 1999 is not representative of the pro forma effect on
net income (loss) in future periods because it does not take into consideration
pro forma compensation expense related to grants made before 1997.
Shareholder rights plan
In January 1997, the board of directors approved a shareholder rights plan
under which shareholders of record on March 31, 1997 received a right to
purchase (the "Right") one-thousandth of a share of Series A participating
preferred stock at an exercise price of $44.00, subject to adjustment. The
Rights will separate from the common stock and Rights certificates will be
issued and will become exercisable on the earlier of: (i) 10 days (or such later
date as may be determined by a majority of the board of directors) following a
public announcement that a person or group of affiliated or associated persons
has acquired, or obtained the right to acquire, beneficial ownership of 15% or
more of the Company's outstanding common stock or (ii) 10 business days
following the commencement of, or announcement of an intention to make, a tender
offer or exchange offer, the consummation of which would result in the
beneficial ownership by a person or group of 15% or more of the Company's
outstanding common stock. The Rights expire on the earlier of (i) January 22,
2007 or (ii) redemption or exchange of the Rights.
7. RETIREMENT SAVINGS PLAN
Effective September 1990, the Company adopted the Cholestech Corporation
Retirement Savings Plan (the "401(k) Plan") in which all employees of the
Company are entitled to participate. An eligible employee may elect to defer, in
the form of contributions to the 401(k) Plan, between 1% and 15% of the
employee's W-2 income, not to exceed $10,500 per year (adjusted for
cost-of-living increases). Employee contributions are invested in selected
mutual funds or a money market fund as specified by the employee. Employee
contributions are fully vested and nonforfeitable at all times. The 401(k) Plan
provides for employer contributions as determined by the board of directors.
Company contributions to the 401(k) Plan were $261,000, $177,000 and $67,000 in
fiscal 2001, 2000 and 1999, respectively.
8. ACQUISITION
On January 21, 2000, the Company completed the purchase of certain assets
of Health Net, Inc., a Louisiana corporation ("Health Net"). As consideration
the Company paid approximately $2,499,000 in cash and issued 51,010 shares of
its common stock valued at approximately $300,000. The Purchase Agreement also
provided for an additional amount of cash consideration, up to $1,000,000, to be
paid to the former owners of Health Net for achieving certain performance
milestones for the calendar year ending December 31, 2000. The actual amount
earned and paid to the aforementioned was $862,000 and was paid on March 29,
2001 from an escrow account. The $1.0 million was classified as restricted cash
on the balance sheet at March 31, 2000. In addition to the Earnout, goodwill of
$330,000 was created during fiscal 2001 from the final purchase audit results
and a negotiation resolution.
Health Net marketed and administered medical diagnostic testing services
for various venue events, corporations and pharmacies. After the acquisition,
Health Net's marketing and administrative functions have been incorporated into
WellCheck, the Company's new testing service business which is responsible for
ongoing testing programs in retail venues, corporate facilities and other sites
convenient to consumers.
F-16
67
CHOLESTECH CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
The acquisition was accounted for using the purchase method of accounting
and the results of Health Net have been included in the Company's consolidated
financial statements subsequent to January 21, 2000. The allocation of the
estimated purchase price to the tangible and intangible assets acquired in
connection with this acquisition was based on estimated fair values as
determined by management as follows (in thousands):
Total current assets........................................ $ 285
Property and equipment and other noncurrent assets.......... 107
Goodwill.................................................... 3,952
------
Total purchase price.............................. $4,344
======
The following unaudited pro forma information reflects the results of
operations as if the Company had acquired Health Net at the beginning of each
period presented:
FISCAL YEAR ENDED
-------------------------------------
MARCH 31, 2000 MARCH 26, 1999
---------------- ----------------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(UNAUDITED)
Revenue:
As reported.................................. $27,422 $22,032
Pro forma.................................... $28,777 $22,734
Net income (loss):
As reported.................................. $ 3,132 $ (73)
Pro forma...................................... $ 2,848 $ (595)
Net income (loss) per share:
As reported -- basic......................... $ 0.27 $ (0.01)
Pro forma -- basic........................... $ 0.24 $ (0.05)
As reported -- diluted....................... $ 0.26 $ (0.01)
Pro forma -- diluted......................... $ 0.24 $ (0.05)
9. INCOME TAXES
No provision was recorded for the year ended March 30, 2001 as the Company
incurred a net operating loss for income tax purposes. A provision for income
taxes of $129,000, all of which is current, was recorded for the year ended
March 31, 2000. No provision was recorded for the year ended March 26, 1999 as
the Company incurred net operating loss for income tax purposes.
The differences between the U.S. federal statutory income tax rate and the
Company's effective tax rate for fiscal 2000 are as follows:
FISCAL YEAR ENDED
MARCH 31, 2000
-----------------
Provision at statutory rate.......................... 34.0%
State taxes, net of federal benefit.................. 5.6
Stock options........................................ (2.4)
Utilization of research and development credits...... (34.7)
Other................................................ 1.4
3.9%
=====
The differences between the U. S. Federal statutory income tax rate and the
Company's effective tax rate for fiscal 1999 and 2001 relate primarily to losses
for which no benefit was recognized.
F-17
68
CHOLESTECH CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
Deferred tax assets (liabilities) consist of the following (in thousands):
MARCH 30, 2001 MARCH 31, 2000
-------------- --------------
Net operating loss carryforwards................ $ 15,334 $ 14,073
Research and development tax credit
carryforwards................................. 2,641 2,426
Minimum tax credit carryforwards................ 164 186
Capitalized research and development............ 920 756
Other........................................... (100) 416
Valuation allowance for deferred tax assets..... (18,959) (17,857)
-------- --------
$ -- $ --
======== ========
The Company has historically experienced significant operating losses and
operates in an industry subject to rapid technological changes. Therefore,
management believes that there is sufficient uncertainty regarding the Company's
ability to generate future taxable income and utilize its net operating loss and
tax credit carryforwards such that a full valuation allowance for deferred tax
assets was required at March 30, 2001.
At March 30, 2001 the Company has net operating loss carryforwards
available to reduce future taxable income through 2021 for federal tax purposes
and through 2006 for state income tax purposes of approximately $44,259,000 and
$3,240,000, respectively. Additionally, the Company has research and development
and other tax credit carryforwards available to reduce income taxes for federal
and state income tax purposes of approximately $1,873,000 and $768,000,
respectively.
As a result of a change in ownership which occurred in May 1990, there is
an annual limitation of approximately $1,500,000 for federal and state income
tax purposes on the combined use of approximately $6,131,000 of federal net
operating loss carryforwards and the use of approximately $550,000 of federal
and state tax credit carryforwards.
10. SEGMENT INFORMATION
In fiscal 2000, the Company adopted Statement of Financial Accounting
Standard ("SFAS") 131, "Disclosures about Segments of an Enterprise and Related
Information." During fiscal 2000, the Company launched two new business units,
WellCheck and WellCheck.com. As a result, the Company had three reportable
segments: Diagnostic Products, WellCheck and WellCheck.com. These segments are
strategic business units that offer different products and as a result are
managed separately. The accounting policies of the segments are the same as
those described in Note 1 -- Summary of Significant Accounting Policies. Segment
data includes a charge allocating all corporate-headquarters costs to each of
its operating segments and excludes inter-segment revenue. Before fiscal 2000
the Company operated in one segment, the Diagnostic Products business unit.
Asset information by segment has not been presented as the Company does not
produce such information.
F-18
69
CHOLESTECH CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
Results for fiscal 2001 by segment are as follows (in thousands):
DIAGNOSTIC
PRODUCTS WELLCHECK WELLCHECK.COM CHOLESTECH
---------- --------- ------------- ----------
Net revenue................................. $32,489 $ 4,429 $ 85 $37,003
Cost of revenue............................. 14,055 1,225 -- 15,280
------- ------- ------- -------
Gross profit................................ 18,434 3,204 85 21,723
------- ------- ------- -------
Operating expenses:
Sales and marketing......................... 7,969 2,736 683 11,388
Research and development.................. 2,194 -- 392 2,586
Website and related costs................. -- -- 1,952 1,952
General and administrative................ 2,647 1,143 1,289 5,079
Goodwill amortization..................... -- 709 -- 709
Legal and other related................... 438 437 437 1,312
Impairment charge......................... -- -- 1,958 1,958
------- ------- ------- -------
Total operating expenses.......... 13,248 5,025 6,711 24,984
------- ------- ------- -------
Operating income (loss)..................... $ 5,186 $(1,821) $(6,626) $(3,261)
======= ======= ======= =======
The Company has determined that starting in fiscal 2002, WellCheck and
WellCheck.com will operate and be managed as one segment. All future operating
results will show the combined results for WellCheck and WellCheck.com under a
single segment. The wholly owned subsidiary WellCheck.com was legally merged
into WellCheck effective June 22, 2001.
11. GEOGRAPHIC INFORMATION
The Company's export sales were $6,460,000, $4,859,000 and $2,836,000 for
fiscal 2001, 2000 and 1999, respectively. Sales to Europe were $5,133,000,
$3,960,000 and $2,069,000 in fiscal 2001, 2000 and 1999, respectively, with the
remainder of export sales to the Pacific Rim and Latin America. All of the
Company's assets are located in the United States.
F-19
70
SCHEDULE II
CHOLESTECH CORPORATION
VALUATION AND QUALIFYING ACCOUNTS
BALANCE AT ADDITIONS TO BALANCE AT
BEGINNING COSTS & END OF
OF PERIOD EXPENSES DEDUCTIONS PERIOD
---------- ------------ ---------- ----------
FISCAL YEAR ENDED MARCH 26, 1999
Allowance for doubtful accounts.................... $110,000 $ 2,000 $ 37,000 $ 75,000
Inventory reserve.................................. 163,000 152,000 95,000 220,000
FISCAL YEAR ENDED MARCH 31, 2000
Allowance for doubtful accounts.................... $ 75,000 $269,000 207,000 $137,000
Allowance for sales returns........................ -- 83,000 -- 83,000
Inventory reserve.................................. 220,000 57,000 98,000 179,000
FISCAL YEAR ENDED MARCH 30, 2001
Allowance for doubtful accounts.................... $137,000 $224,000 $270,000 $ 91,000
Allowance for sales returns........................ 83,000 -- -- 83,000
Inventory reserve.................................. 179,000 107,000 60,000 226,000
All other Schedules for which provision is made in the applicable
accounting regulations of the Securities and Exchange Commission are not
required under the related instructions or are inapplicable, and therefore have
been omitted.
F-20
71
EXHIBIT INDEX
EXHIBIT
NUMBER DESCRIPTION
------- -----------
3.1(1) Restated Articles of Incorporation of Registrant
3.2(2) Bylaws of Registrant, as amended
4.2(3) Preferred Share Rights Agreement dated January 22, 1997
between Registrant and Chase Mellon Shareholder Services,
L.L.C., including the Certificate of Determination, the form
of Rights Certificate and Summary of Rights attached thereto
as Exhibits A, B and C, respectively
10.1(4) 1988 Stock Incentive Program and forms of agreements
thereunder
10.2(5) 1992 Employee Stock Purchase Plan
10.3(2) Standard Industrial Lease Agreement between Registrant and
Sunlife Assurance Company of Canada dated October 22, 1989
10.3.1(6) First Amendment to Standard Industrial Lease Agreement
between Registrant and Sunlife Assurance Company of Canada
dated April, 1995
10.4(2) Forms of Indemnification Agreements between Registrant and
its officers and its directors
10.5 Reserved
10.6 Reserved
10.6.1 Reserved
10.7 Reserved
10.7.1 Reserved
10.8 Reserved
10.9 Reserved
10.10 Reserved
10.11.1 Reserved
10.11.2 Reserved
10.11.3 Reserved
10.11.4 Reserved
10.11.5 Reserved
10.11.6 Reserved
10.11.7 Reserved
10.12 Reserved
10.13 Reserved
10.14 Reserved
10.15 Reserved
10.16 Reserved
10.17.1(7) Letter Agreement effective December 20, 1996 by and between
Wells Fargo Bank and Registrant
10.17.2(7) Revolving Line of Credit Note effective December 20, 1996 by
and between Wells Fargo Bank and Registrant
10.17.3(7) General Pledge Agreement effective December 20, 1996 by and
between Wells Fargo Bank and Registrant
10.17.4(8) Revolving Line of Credit Note effective November 30, 1997 by
and between Wells Fargo Bank and Registrant
10.17.5(9) Revolving Line of Credit Note effective November 30, 1998 by
and between Wells Fargo Bank and Registrant
72
EXHIBIT
NUMBER DESCRIPTION
------- -----------
10.17.6(10) Revolving line of Credit Note Effective November 30, 1999 by
and between Wells Fargo Bank and Registrant
10.17.7(11) Revolving line of Credit Note effective May 1, 2000 by and
between Wells Fargo Bank and Registrant
10.18 Reserved
10.19 Reserved
10.20(12) 1997 Stock Incentive Program and Form of Agreement
thereunder
10.21(13) 1999 Nonstatutory Stock Option Plan and Form of Agreement
thereunder
10.21.1(14) Distribution Agreement between Registrant and McKesson Drug
Company dated August 18, 1998
10.21.2(14) Distribution Agreement between Registrant and Bergen
Brunswig Corporation dated July 20, 1998
10.22 Reserved
10.23(15) Employment Agreement between Registrant and Robert J.
Dominici dated July 15, 1998
10.24(16) Employment Agreement between Registrant and Jeffrey S. Aroy
dated September 3, 1999
10.25(11) Employment Agreement between Registrant and Thomas E. Worthy
dated August 6, 1999
10.26(11) Employment Agreement between Registrant and Terry L.
Wassmann dated March 28, 2000
10.27(11) Employment Agreement between Registrant and Kevin R.
Stromberg dated March 27, 2000
10.28(11) Employment Agreement between Registrant and Timothy I. Still
dated October 6, 1999
10.29(17) 2000 Stock Incentive Program and Form of Agreement
thereunder
10.30* Letter Agreement between Registrant and GMR Marketing, Inc.
dated January 23, 2001
10.31 Amendment to the Letter Agreement between Registrant and GMR
Marketing, Inc. dated April 30, 2001
10.32 Employment Agreement between Registrant and William W. Burke
dated March 14, 2001
10.33 Lease Agreement between Registrant and Terradev Jefferson
LLC dated July 28, 2000
10.34 Second Amendment to Standard Industrial Lease Agreement
between Registrant and Sunlife Assurance Company of Canada
dated March 17, 1995
10.35 Third Amendment to Standard Industrial Lease Agreement
between Registrant and Sunlife Assurance Company of Canada
dated January 27, 1997
10.36 Fourth Amendment to Standard Industrial Lease Agreement
between Registrant and The BIV Group (successor-in-interest
to Sunlife Assurance Company of Canada) dated March 3, 2000
10.3.2 Reserved
10.3.3 Reserved
21.1 Subsidiaries
23.1 Consent of Independent Accountants
---------------
* Confidential treatment has been requested from the Securities and Exchange
Commission with respect to certain portions of this exhibit. The redacted
portions have been filed separately with the Securities and Exchange
Commission.
(1) Incorporated by reference to exhibits filed with Registrant's Registration
Statement on Form S-1 (No. 33-54300) as declared effective by the
Securities and Exchange Commission on December 16, 1992.
(2) Incorporated by reference to exhibits filed with Registrant's Registration
Statement on Form S-1 (No. 33-47603) as declared effective by the
Securities and Exchange Commission on June 26, 1992.
(3) Incorporated by reference to exhibits filed with Registrant's Registration
Statement on Form 8-A (No. 000-20198) as declared effective by the
Securities and Exchange Commission on March 27, 1997.
(4) Incorporated by reference to exhibits filed with Registrant's Registration
Statement on Form S-8 (No. 333-22475) as declared effective by the
Securities and Exchange Commission on February 28, 1997.
73
(5) Incorporated by reference to exhibits filed with Registrant's Registration
Statement on Form S-8 (No. 333-38147) as declared effective by the
Securities and Exchange Commission on October 17, 1997, as amended by
Registrant's Registration Statement on Form S-8 (No. 333-38147) as declared
effective by the Securities and Exchange Commission on October 17, 1997, as
amended by Registrant's Registration Statement on Form S-8 (No. 333-44980)
as declared effective by the Securities and Exchange Commission on August
31, 2000.
(6) Incorporated by reference to exhibits filed with Registrant's Quarterly
Report on Form 10-Q for the quarter ended June 30, 1995.
(7) Incorporated by reference to exhibits filed with Registrant's Quarterly
Report on Form 10-Q for the quarter ended December 27, 1996.
(8) Incorporated by reference to exhibits filed with Registrant's Quarterly
Report on Form 10-Q for the quarter ended December 26, 1997.
(9) Incorporated by reference to exhibits filed with Registrant's Quarterly
Report on Form 10-Q for the quarter ended December 25, 1998.
(10) Incorporated by reference to exhibits filed with Registrant's Quarterly
Report on Form 10-Q for the quarter ended December 24, 1999.
(11) Incorporated by reference to exhibits filed with Registrant's Annual Report
on Form 10-K for the fiscal year ended March 31, 2000.
(12) Incorporated by reference to exhibits filed with Registrant's Registration
Statement on Form S-8 (No. 333-38151) as declared effective by the
Securities and Exchange Commission on October 17, 1997.
(13) Incorporated by reference to exhibits filed with Registrant's Registration
Statement on Form S-8 (No. 333-94503) as declared effective by the
Securities and Exchange Commission on January 12, 2000.
(14) Incorporated by reference to exhibits filed with Registrant's Quarterly
Report on Form 10-Q for the quarter ended September 25, 1998.
(15) Incorporated by reference to exhibits filed with Registrant's Quarterly
Report on Form 10-Q for the quarter ended June 25, 1999.
(16) Incorporated by reference to exhibits filed with Registrant's Quarterly
Report on Form 10-Q for the quarter ended September 24, 1999.
(17) Incorporated by reference to exhibits filed with Registrant's Registration
Statement on Form S-8 (333-44980) as declared effective by the Securities
and Exchange Commission on August 31, 2000.